PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5493586

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		

CONVEYING PARTY DATA

Name	Execution Date	
OXFORD FINANCE LLC	04/23/2019	

RECEIVING PARTY DATA

Name:	CYTORI THERAPEUTICS, INC.	
Street Address:	3020 CALLAN ROAD	
City:	SAN DIEGO	
State/Country:	CALIFORNIA	
Postal Code:	92121	

PROPERTY NUMBERS Total: 162

Property Type	Number
Patent Number:	7687059
Patent Number:	9198937
Patent Number:	7585670
Patent Number:	8163276
Patent Number:	7514075
Patent Number:	7651684
Patent Number:	8246947
Patent Number:	7595043
Patent Number:	7771716
Patent Number:	9504716
Patent Number:	8404229
Patent Number:	8105580
Patent Number:	8337834
Patent Number:	7473420
Patent Number:	7501115
Patent Number:	7390484
Patent Number:	8119121
Patent Number:	7901672
Patent Number:	7887795
Patent Number:	7429488

PATENT REEL: 049011 FRAME: 0347

505446785

Property Type	Number
Patent Number:	9511094
Patent Number:	8883499
Patent Number:	10119113
Patent Number:	8771678
Patent Number:	9463203
Patent Number:	9504718
Patent Number:	9872877
Patent Number:	8691216
Patent Number:	9492483
Patent Number:	9511096
Patent Number:	9480718
Patent Number:	9849149
Patent Number:	8784801
Patent Number:	9486484
Patent Number:	9597395
Application Number:	60462911
Application Number:	10316127
Application Number:	14954584
Application Number:	15844091
Application Number:	10783957
Application Number:	10884861
Application Number:	12414582
Application Number:	12568533
Application Number:	10885294
Application Number:	10884871
Application Number:	12494211
Application Number:	14537724
Application Number:	15462643
Application Number:	13598203
Application Number:	15366924
Application Number:	15833813
Application Number:	15362713
Application Number:	15846950
Application Number:	15362249
Application Number:	15877324
Application Number:	13296075
Application Number:	15847709
Application Number:	14629305

Property Type	Number
Application Number:	60496467
Application Number:	60503589
Application Number:	60479418
Application Number:	13926854
Application Number:	14860416
Application Number:	12302787
Application Number:	60685206
Application Number:	60693323
Application Number:	12090241
Application Number:	60727174
Application Number:	60730153
Application Number:	60730127
Application Number:	60793422
Application Number:	60793421
Application Number:	15345294
Application Number:	60795334
Application Number:	60945320
Application Number:	61074299
Application Number:	61090186
Application Number:	12375005
Application Number:	60833561
Application Number:	12188950
Application Number:	60838288
Application Number:	60955252
Application Number:	10242094
Application Number:	60322070
Application Number:	60720060
Application Number:	10325728
Application Number:	60449279
Application Number:	60642954
Application Number:	60482820
Application Number:	60639013
Application Number:	60858161
Application Number:	60903485
Application Number:	11229028
Application Number:	60615140
Application Number:	12766768
Application Number:	13450262

Application Number: 60987738 Application Number: 60987738 Application Number: 61013442 Application Number: 13279090 Application Number: 61172152 Application Number: 61174860 Application Number: 61174860 Application Number: 13120636 Application Number: 61880086 Application Number: 61977466 Application Number: 61938040 Application Number: 61938052 Application Number: 61938052 Application Number: 62038052 Application Number: 62022131 Application Number: 62022131 Application Number: 62059773 Application Number: 62298389 Application Number: 62463508 Application Number: 62463508 Application Number: 62430290 Application Number: 62436260 Application Number: 62436260 Application Number: 11317422 Application Number: 13467828	Property Type	Number
Application Number: 13279090 Application Number: 13720829 Application Number: 61172152 Application Number: 61174860 Application Number: 61174860 Application Number: 13120636 Application Number: 14917441 Application Number: 61880086 Application Number: 61977466 Application Number: 61938040 Application Number: 61938040 Application Number: 61938052 Application Number: 14750932 Application Number: 15324596 Application Number: 62022131 Application Number: 62059773 Application Number: 62298389 Application Number: 62463508 Application Number: 62463508 Application Number: 62430290 Application Number: 62430290 Application Number: 62436260 Application Number: 6263685 Application Number: 62436260 Application Number: 626368243 Application Number: 62636828 Application Number: 62636828 Application Number: 62636828 Application Number: 62436280 Application Number: 62436280 Application Number: 62436280 Application Number: 62436288 Application Number: 62636828 Application Number: 11317422 Application Number: 11317422	Application Number:	60983054
Application Number: 13279090 Application Number: 13720829 Application Number: 61172152 Application Number: 61174860 Application Number: 13120636 Application Number: 14917441 Application Number: 61880086 Application Number: 61977466 Application Number: 61938040 Application Number: 61938052 Application Number: 61938052 Application Number: 15324596 Application Number: 62022131 Application Number: 62059773 Application Number: 62298389 Application Number: 62463508 Application Number: 62463508 Application Number: 62430290 Application Number: 62430290 Application Number: 6263685 Application Number: 62430290 Application Number: 626368243 Application Number: 62608243 Application Number: 62608243 Application Number: 62608288 Application Number: 62608288 Application Number: 6263588 Application Number: 62436280 Application Number: 62436280 Application Number: 62436288 Application Number: 62608243 Application Number: 1317422 Application Number: 13467828 Application Number: 11813579	Application Number:	60987738
Application Number: 61172152 Application Number: 61172152 Application Number: 12771985 Application Number: 61174860 Application Number: 13120636 Application Number: 14917441 Application Number: 61880086 Application Number: 61977466 Application Number: 61938040 Application Number: 61938052 Application Number: 61938052 Application Number: 15324596 Application Number: 62022131 Application Number: 62059773 Application Number: 62298389 Application Number: 62463508 Application Number: 62635685 Application Number: 62430290 Application Number: 62436260 Application Number: 62608243 Application Number: 62608243 Application Number: 13467828 Application Number: 11813579	Application Number:	61013442
Application Number: 12771985 Application Number: 61174860 Application Number: 13120636 Application Number: 14917441 Application Number: 61880086 Application Number: 61977466 Application Number: 61938040 Application Number: 61938052 Application Number: 14750932 Application Number: 15324596 Application Number: 62022131 Application Number: 15515870 Application Number: 62298389 Application Number: 62463508 Application Number: 62463508 Application Number: 62430290 Application Number: 62436260 Application Number: 62608243 Application Number: 62608243 Application Number: 6260828 Application Number: 6260828 Application Number: 6246328 Application Number: 62467828 Application Number: 61317422 Application Number: 11317422 Application Number: 13467828 Application Number: 11813579	Application Number:	13279090
Application Number: 61174860 Application Number: 61174860 Application Number: 13120636 Application Number: 14917441 Application Number: 6188086 Application Number: 61977466 Application Number: 61938040 Application Number: 61938052 Application Number: 61938052 Application Number: 14750932 Application Number: 15324596 Application Number: 62022131 Application Number: 62059773 Application Number: 62298389 Application Number: 62463508 Application Number: 62430290 Application Number: 62430290 Application Number: 62608243 Application Number: 62608243 Application Number: 13467828 Application Number: 13467828 Application Number: 131813579	Application Number:	13720829
Application Number: 61174860 Application Number: 13120636 Application Number: 14917441 Application Number: 61880086 Application Number: 61977466 Application Number: 61938040 Application Number: 61938052 Application Number: 14750932 Application Number: 62022131 Application Number: 62022131 Application Number: 62059773 Application Number: 62298389 Application Number: 62463508 Application Number: 62463508 Application Number: 62430290 Application Number: 62436260 Application Number: 62608243 Application Number: 11317422 Application Number: 13467828 Application Number: 1313579	Application Number:	61172152
Application Number: 13120636 Application Number: 14917441 Application Number: 61880086 Application Number: 61977466 Application Number: 61938040 Application Number: 61938052 Application Number: 14750932 Application Number: 15324596 Application Number: 62022131 Application Number: 15515870 Application Number: 62298389 Application Number: 62463508 Application Number: 62463508 Application Number: 62430290 Application Number: 62436260 Application Number: 62608243 Application Number: 1317422 Application Number: 13467828 Application Number: 13467828 Application Number: 13467828 Application Number: 11813579	Application Number:	12771985
Application Number: 14917441 Application Number: 61880086 Application Number: 61977466 Application Number: 15117665 Application Number: 61938040 Application Number: 61938052 Application Number: 14750932 Application Number: 62022131 Application Number: 62022131 Application Number: 62059773 Application Number: 62298389 Application Number: 62463508 Application Number: 62635685 Application Number: 62430290 Application Number: 62436260 Application Number: 62608243 Application Number: 11317422 Application Number: 13467828 Application Number: 13467828 Application Number: 11813579	Application Number:	61174860
Application Number: 61880086 Application Number: 61977466 Application Number: 15117665 Application Number: 61938040 Application Number: 61938052 Application Number: 14750932 Application Number: 62022131 Application Number: 15515870 Application Number: 62059773 Application Number: 62298389 Application Number: 6243508 Application Number: 62435685 Application Number: 62430290 Application Number: 62436260 Application Number: 62608243 Application Number: 11317422 Application Number: 13467828 Application Number: 11813579	Application Number:	13120636
Application Number: 61977466 Application Number: 15117665 Application Number: 61938040 Application Number: 61938052 Application Number: 14750932 Application Number: 15324596 Application Number: 62022131 Application Number: 15515870 Application Number: 62059773 Application Number: 62298389 Application Number: 62463508 Application Number: 62635685 Application Number: 62430290 Application Number: 62430290 Application Number: 62436260 Application Number: 62608243 Application Number: 11317422 Application Number: 13467828 Application Number: 11813579	Application Number:	14917441
Application Number: 61938040 Application Number: 61938052 Application Number: 14750932 Application Number: 15324596 Application Number: 62022131 Application Number: 15515870 Application Number: 62059773 Application Number: 62298389 Application Number: 62463508 Application Number: 62635685 Application Number: 62430290 Application Number: 62430290 Application Number: 62436260 Application Number: 62608243 Application Number: 11317422 Application Number: 13467828 Application Number: 13467828 Application Number: 11813579	Application Number:	61880086
Application Number: 61938040 Application Number: 61938052 Application Number: 14750932 Application Number: 15324596 Application Number: 62022131 Application Number: 15515870 Application Number: 62059773 Application Number: 62298389 Application Number: 62463508 Application Number: 62635685 Application Number: 16331427 Application Number: 62430290 Application Number: 62436260 Application Number: 62608243 Application Number: 11317422 Application Number: 13467828 Application Number: 13467828 Application Number: 11813579	Application Number:	61977466
Application Number: 61938052 Application Number: 14750932 Application Number: 62022131 Application Number: 62059773 Application Number: 62298389 Application Number: 62463508 Application Number: 62635685 Application Number: 62430290 Application Number: 62436260 Application Number: 62436260 Application Number: 62608243 Application Number: 1317422 Application Number: 13467828 Application Number: 13467828 Application Number: 11813579	Application Number:	15117665
Application Number: 14750932 Application Number: 15324596 Application Number: 62022131 Application Number: 15515870 Application Number: 62059773 Application Number: 62298389 Application Number: 62463508 Application Number: 62635685 Application Number: 16331427 Application Number: 62430290 Application Number: 62436260 Application Number: 62608243 Application Number: 11317422 Application Number: 13467828 Application Number: 13467828 Application Number: 11813579	Application Number:	61938040
Application Number: 15324596 Application Number: 62022131 Application Number: 15515870 Application Number: 62059773 Application Number: 62298389 Application Number: 62463508 Application Number: 62635685 Application Number: 16331427 Application Number: 62430290 Application Number: 62436260 Application Number: 62608243 Application Number: 11317422 Application Number: 13467828 Application Number: 13467828 Application Number: 11813579	Application Number:	61938052
Application Number: 62022131 Application Number: 15515870 Application Number: 62059773 Application Number: 62298389 Application Number: 62463508 Application Number: 62635685 Application Number: 16331427 Application Number: 62430290 Application Number: 62436260 Application Number: 62608243 Application Number: 11317422 Application Number: 13467828 Application Number: 13813579	Application Number:	14750932
Application Number: 15515870 Application Number: 62059773 Application Number: 62298389 Application Number: 62463508 Application Number: 62635685 Application Number: 16331427 Application Number: 62430290 Application Number: 62436260 Application Number: 62608243 Application Number: 11317422 Application Number: 13467828 Application Number: 11813579	Application Number:	15324596
Application Number: 62059773 Application Number: 62298389 Application Number: 62463508 Application Number: 62635685 Application Number: 16331427 Application Number: 62430290 Application Number: 62436260 Application Number: 62608243 Application Number: 11317422 Application Number: 13467828 Application Number: 11813579	Application Number:	62022131
Application Number: 62298389 Application Number: 62463508 Application Number: 62635685 Application Number: 16331427 Application Number: 62430290 Application Number: 62436260 Application Number: 62608243 Application Number: 11317422 Application Number: 13467828 Application Number: 11813579	Application Number:	15515870
Application Number: 62463508 Application Number: 62635685 Application Number: 16331427 Application Number: 62430290 Application Number: 62436260 Application Number: 62608243 Application Number: 11317422 Application Number: 13467828 Application Number: 11813579	Application Number:	62059773
Application Number: 62635685 Application Number: 16331427 Application Number: 62430290 Application Number: 62436260 Application Number: 62608243 Application Number: 11317422 Application Number: 13467828 Application Number: 11813579	Application Number:	62298389
Application Number: 16331427 Application Number: 62430290 Application Number: 62436260 Application Number: 62608243 Application Number: 11317422 Application Number: 13467828 Application Number: 11813579	Application Number:	62463508
Application Number: 62430290 Application Number: 62436260 Application Number: 62608243 Application Number: 11317422 Application Number: 13467828 Application Number: 11813579	<u>'''</u>	
Application Number: 62436260 Application Number: 62608243 Application Number: 11317422 Application Number: 13467828 Application Number: 11813579	Application Number:	16331427
Application Number:62608243Application Number:11317422Application Number:13467828Application Number:11813579	Application Number:	62430290
Application Number: 11317422 Application Number: 13467828 Application Number: 11813579	Application Number:	62436260
Application Number: 13467828 Application Number: 11813579	Application Number:	62608243
Application Number: 11813579	Application Number:	11317422
	Application Number:	13467828
I I S 2004 00 5 1 1 7	• •	11813579
032004003117	PCT Number:	US2004005117
PCT Number: US2005018605	PCT Number:	US2005018605
PCT Number: US2004021391	PCT Number:	US2004021391
PCT Number: US2004021418	PCT Number:	US2004021418
PCT Number: US2004021483	PCT Number:	US2004021483
PCT Number: US2004021419	PCT Number:	US2004021419
PCT Number: US2004021549	PCT Number:	US2004021549
PCT Number: US2004021415	PCT Number:	US2004021415

Property Type	Number				
PCT Number:	US2002039465				
PCT Number:	US2004020594				
PCT Number:	US2004021480				
PCT Number:	US2004019611				
PCT Number:	US2006021017				
PCT Number:	US2006040221				
PCT Number:	US2009054055				
PCT Number:	US2007016750				
PCT Number:	US0229207				
PCT Number:	US0240921				
PCT Number:	US2005046926				
PCT Number:	US2007023646				
PCT Number:	US2008054921				
PCT Number:	US2005033329				
PCT Number:	US2008081012				
PCT Number:	US2008086470				
PCT Number:	US2010032275				
PCT Number:	US2010033283				
PCT Number:	JP2009068237				
PCT Number:	JP2009066371				
PCT Number:	US2014056145				
PCT Number:	US2015015028				
PCT Number:	US2015039250				
PCT Number:	US2015053856				
PCT Number:	US2019018176				
PCT Number:	US2016056043				
PCT Number:	US2005001267				
PCT Number:	US2004021417				

CORRESPONDENCE DATA

(202)747-1901 **Fax Number:**

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (858) 720-8900

Email: DMIPDocketing@sheppardmullin.com, STrader@sheppardmullin.com

Correspondent Name: SHEPPARD MULLIN RICHTER & HAMPTON LLP

650 TOWN CENTER DRIVE Address Line 1:


Address Line 2: 4TH FLOOR

Address Line 4: COSTA MESA, CALIFORNIA 92626

ATTORNEY DOCKET NUMBER:	65AS-288114
NAME OF SUBMITTER:	SUSAN TRADER
SIGNATURE:	/Susan Trader/
DATE SIGNED:	04/25/2019

Total Attachments: 103 source=Cytori Release of Security Interest#page1.tif source=Cytori Release of Security Interest#page2.tif source=Cytori Release of Security Interest#page3.tif source=Cytori_Release_of_Security_Interest#page4.tif source=Cytori_Release_of_Security_Interest#page5.tif source=Cytori Release of Security Interest#page6.tif source=Cytori Release of Security Interest#page7.tif source=Cytori_Release_of_Security_Interest#page8.tif source=Cytori Release of Security Interest#page9.tif source=Cytori Release of Security Interest#page10.tif source=Cytori Release of Security Interest#page11.tif source=Cytori_Release_of_Security_Interest#page12.tif source=Cytori Release of Security Interest#page13.tif source=Cytori Release of Security Interest#page14.tif source=Cytori Release of Security Interest#page15.tif source=Cytori_Release_of_Security_Interest#page16.tif source=Cytori Release of Security Interest#page17.tif source=Cytori Release of Security Interest#page18.tif source=Cytori Release of Security Interest#page19.tif source=Cytori Release of Security Interest#page20.tif source=Cytori_Release_of_Security_Interest#page21.tif source=Cytori_Release_of_Security_Interest#page22.tif source=Cytori_Release_of_Security_Interest#page23.tif source=Cytori Release of Security Interest#page24.tif source=Cytori_Release_of_Security_Interest#page25.tif source=Cytori_Release_of_Security_Interest#page26.tif source=Cytori Release of Security Interest#page27.tif source=Cytori Release of Security Interest#page28.tif source=Cytori_Release_of_Security_Interest#page29.tif source=Cytori Release of Security Interest#page30.tif source=Cytori Release of Security Interest#page31.tif source=Cytori Release of Security Interest#page32.tif source=Cytori_Release_of_Security_Interest#page33.tif source=Cytori Release of Security Interest#page34.tif source=Cytori Release of Security Interest#page35.tif source=Cytori Release of Security Interest#page36.tif source=Cytori Release of Security Interest#page37.tif source=Cytori_Release_of_Security_Interest#page38.tif source=Cytori_Release_of_Security_Interest#page39.tif source=Cytori Release of Security Interest#page40.tif source=Cytori Release of Security Interest#page41.tif source=Cytori Release of Security Interest#page42.tif

source=Cytori_Release_of_Security_Interest#page44.tif source=Cytori_Release_of_Security_Interest#page45.tif source=Cytori_Release_of_Security_Interest#page46.tif source=Cytori_Release_of_Security_Interest#page47.tif source=Cytori_Release_of_Security_Interest#page49.tif source=Cytori_Release_of_Security_Interest#page49.tif source=Cytori_Release_of_Security_Interest#page50.tif source=Cytori_Release_of_Security_Interest#page51.tif source=Cytori_Release_of_Security_Interest#page52.tif source=Cytori_Release_of_Security_Interest#page53.tif source=Cytori_Release_of_Security_Interest#page54.tif source=Cytori_Release_of_Security_Interest#page55.tif source=Cytori_Release_of_Security_Interest#page55.tif source=Cytori_Release_of_Security_Interest#page56.tif source=Cytori_Release_of_Security_Interest#page57.tif source=Cytori_Release_of_Security_Interest#page57.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page61.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page64.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page67.tif source=Cytori_Release_of_Security_Interest#page67.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page8	source=Cytori_Release_of_Security_Interest#page43.tif
source=Cytori_Release_of_Security_Interest#page46.tif source=Cytori_Release_of_Security_Interest#page47.tif source=Cytori_Release_of_Security_Interest#page48.tif source=Cytori_Release_of_Security_Interest#page50.tif source=Cytori_Release_of_Security_Interest#page50.tif source=Cytori_Release_of_Security_Interest#page50.tif source=Cytori_Release_of_Security_Interest#page52.tif source=Cytori_Release_of_Security_Interest#page53.tif source=Cytori_Release_of_Security_Interest#page54.tif source=Cytori_Release_of_Security_Interest#page54.tif source=Cytori_Release_of_Security_Interest#page55.tif source=Cytori_Release_of_Security_Interest#page56.tif source=Cytori_Release_of_Security_Interest#page56.tif source=Cytori_Release_of_Security_Interest#page59.tif source=Cytori_Release_of_Security_Interest#page61.tif source=Cytori_Release_of_Security_Interest#page61.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page64.tif source=Cytori_Release_of_Security_Interest#page64.tif source=Cytori_Release_of_Security_Interest#page64.tif source=Cytori_Release_of_Security_Interest#page67.tif source=Cytori_Release_of_Security_Interest#page67.tif source=Cytori_Release_of_Security_Interest#page67.tif source=Cytori_Release_of_Security_Interest#page69.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page8	source=Cytori_Release_of_Security_Interest#page44.tif
source=Cytori_Release_of_Security_Interest#page47.tif source=Cytori_Release_of_Security_Interest#page48.tif source=Cytori_Release_of_Security_Interest#page50.tif source=Cytori_Release_of_Security_Interest#page51.tif source=Cytori_Release_of_Security_Interest#page51.tif source=Cytori_Release_of_Security_Interest#page52.tif source=Cytori_Release_of_Security_Interest#page53.tif source=Cytori_Release_of_Security_Interest#page53.tif source=Cytori_Release_of_Security_Interest#page54.tif source=Cytori_Release_of_Security_Interest#page55.tif source=Cytori_Release_of_Security_Interest#page55.tif source=Cytori_Release_of_Security_Interest#page55.tif source=Cytori_Release_of_Security_Interest#page55.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page61.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page64.tif source=Cytori_Release_of_Security_Interest#page65.tif source=Cytori_Release_of_Security_Interest#page65.tif source=Cytori_Release_of_Security_Interest#page67.tif source=Cytori_Release_of_Security_Interest#page67.tif source=Cytori_Release_of_Security_Interest#page67.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page74.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page8	source=Cytori_Release_of_Security_Interest#page45.tif
source=Cytori_Release_of_Security_Interest#page48.tif source=Cytori_Release_of_Security_Interest#page50.tif source=Cytori_Release_of_Security_Interest#page51.tif source=Cytori_Release_of_Security_Interest#page51.tif source=Cytori_Release_of_Security_Interest#page52.tif source=Cytori_Release_of_Security_Interest#page53.tif source=Cytori_Release_of_Security_Interest#page53.tif source=Cytori_Release_of_Security_Interest#page55.tif source=Cytori_Release_of_Security_Interest#page55.tif source=Cytori_Release_of_Security_Interest#page55.tif source=Cytori_Release_of_Security_Interest#page55.tif source=Cytori_Release_of_Security_Interest#page55.tif source=Cytori_Release_of_Security_Interest#page59.tif source=Cytori_Release_of_Security_Interest#page60.tif source=Cytori_Release_of_Security_Interest#page61.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page65.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page69.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page72.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page8	source=Cytori_Release_of_Security_Interest#page46.tif
source=Cytori_Release_of_Security_Interest#page50.tif source=Cytori_Release_of_Security_Interest#page51.tif source=Cytori_Release_of_Security_Interest#page51.tif source=Cytori_Release_of_Security_Interest#page52.tif source=Cytori_Release_of_Security_Interest#page53.tif source=Cytori_Release_of_Security_Interest#page54.tif source=Cytori_Release_of_Security_Interest#page55.tif source=Cytori_Release_of_Security_Interest#page55.tif source=Cytori_Release_of_Security_Interest#page55.tif source=Cytori_Release_of_Security_Interest#page59.tif source=Cytori_Release_of_Security_Interest#page59.tif source=Cytori_Release_of_Security_Interest#page59.tif source=Cytori_Release_of_Security_Interest#page60.tif source=Cytori_Release_of_Security_Interest#page61.tif source=Cytori_Release_of_Security_Interest#page62.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page64.tif source=Cytori_Release_of_Security_Interest#page65.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page69.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page72.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page8	source=Cytori_Release_of_Security_Interest#page47.tif
source=Cytori_Release_of_Security_Interest#page50.tif source=Cytori_Release_of_Security_Interest#page51.tif source=Cytori_Release_of_Security_Interest#page52.tif source=Cytori_Release_of_Security_Interest#page53.tif source=Cytori_Release_of_Security_Interest#page54.tif source=Cytori_Release_of_Security_Interest#page55.tif source=Cytori_Release_of_Security_Interest#page55.tif source=Cytori_Release_of_Security_Interest#page55.tif source=Cytori_Release_of_Security_Interest#page55.tif source=Cytori_Release_of_Security_Interest#page59.tif source=Cytori_Release_of_Security_Interest#page59.tif source=Cytori_Release_of_Security_Interest#page60.tif source=Cytori_Release_of_Security_Interest#page61.tif source=Cytori_Release_of_Security_Interest#page62.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page64.tif source=Cytori_Release_of_Security_Interest#page65.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page67.tif source=Cytori_Release_of_Security_Interest#page69.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page72.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page8	source=Cytori_Release_of_Security_Interest#page48.tif
source=Cytori_Release_of_Security_Interest#page51.tif source=Cytori_Release_of_Security_Interest#page52.tif source=Cytori_Release_of_Security_Interest#page53.tif source=Cytori_Release_of_Security_Interest#page54.tif source=Cytori_Release_of_Security_Interest#page55.tif source=Cytori_Release_of_Security_Interest#page56.tif source=Cytori_Release_of_Security_Interest#page57.tif source=Cytori_Release_of_Security_Interest#page59.tif source=Cytori_Release_of_Security_Interest#page59.tif source=Cytori_Release_of_Security_Interest#page60.tif source=Cytori_Release_of_Security_Interest#page61.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page64.tif source=Cytori_Release_of_Security_Interest#page65.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page68.tif source=Cytori_Release_of_Security_Interest#page69.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page72.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page8	source=Cytori_Release_of_Security_Interest#page49.tif
source=Cytori_Release_of_Security_Interest#page52.tif source=Cytori_Release_of_Security_Interest#page53.tif source=Cytori_Release_of_Security_Interest#page54.tif source=Cytori_Release_of_Security_Interest#page55.tif source=Cytori_Release_of_Security_Interest#page56.tif source=Cytori_Release_of_Security_Interest#page57.tif source=Cytori_Release_of_Security_Interest#page58.tif source=Cytori_Release_of_Security_Interest#page59.tif source=Cytori_Release_of_Security_Interest#page60.tif source=Cytori_Release_of_Security_Interest#page60.tif source=Cytori_Release_of_Security_Interest#page61.tif source=Cytori_Release_of_Security_Interest#page62.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page64.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page69.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page72.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page8	source=Cytori_Release_of_Security_Interest#page50.tif
source=Cytori_Release_of_Security_Interest#page53.tif source=Cytori_Release_of_Security_Interest#page54.tif source=Cytori_Release_of_Security_Interest#page55.tif source=Cytori_Release_of_Security_Interest#page56.tif source=Cytori_Release_of_Security_Interest#page57.tif source=Cytori_Release_of_Security_Interest#page58.tif source=Cytori_Release_of_Security_Interest#page59.tif source=Cytori_Release_of_Security_Interest#page60.tif source=Cytori_Release_of_Security_Interest#page61.tif source=Cytori_Release_of_Security_Interest#page62.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page64.tif source=Cytori_Release_of_Security_Interest#page65.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page69.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page72.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page74.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page8	source=Cytori_Release_of_Security_Interest#page51.tif
source=Cytori_Release_of_Security_Interest#page54.tif source=Cytori_Release_of_Security_Interest#page55.tif source=Cytori_Release_of_Security_Interest#page56.tif source=Cytori_Release_of_Security_Interest#page57.tif source=Cytori_Release_of_Security_Interest#page58.tif source=Cytori_Release_of_Security_Interest#page59.tif source=Cytori_Release_of_Security_Interest#page60.tif source=Cytori_Release_of_Security_Interest#page61.tif source=Cytori_Release_of_Security_Interest#page62.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page64.tif source=Cytori_Release_of_Security_Interest#page65.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page69.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page72.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page74.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif	source=Cytori_Release_of_Security_Interest#page52.tif
source=Cytori_Release_of_Security_Interest#page55.tif source=Cytori_Release_of_Security_Interest#page56.tif source=Cytori_Release_of_Security_Interest#page57.tif source=Cytori_Release_of_Security_Interest#page58.tif source=Cytori_Release_of_Security_Interest#page59.tif source=Cytori_Release_of_Security_Interest#page60.tif source=Cytori_Release_of_Security_Interest#page61.tif source=Cytori_Release_of_Security_Interest#page62.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page64.tif source=Cytori_Release_of_Security_Interest#page65.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page67.tif source=Cytori_Release_of_Security_Interest#page69.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page72.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif	source=Cytori_Release_of_Security_Interest#page53.tif
source=Cytori_Release_of_Security_Interest#page56.tif source=Cytori_Release_of_Security_Interest#page57.tif source=Cytori_Release_of_Security_Interest#page58.tif source=Cytori_Release_of_Security_Interest#page59.tif source=Cytori_Release_of_Security_Interest#page60.tif source=Cytori_Release_of_Security_Interest#page61.tif source=Cytori_Release_of_Security_Interest#page62.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page64.tif source=Cytori_Release_of_Security_Interest#page65.tif source=Cytori_Release_of_Security_Interest#page65.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page69.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page72.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page74.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page8	source=Cytori_Release_of_Security_Interest#page54.tif
source=Cytori_Release_of_Security_Interest#page57.tif source=Cytori_Release_of_Security_Interest#page58.tif source=Cytori_Release_of_Security_Interest#page59.tif source=Cytori_Release_of_Security_Interest#page60.tif source=Cytori_Release_of_Security_Interest#page61.tif source=Cytori_Release_of_Security_Interest#page62.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page64.tif source=Cytori_Release_of_Security_Interest#page65.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page68.tif source=Cytori_Release_of_Security_Interest#page69.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page72.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page74.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page79.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif	source=Cytori_Release_of_Security_Interest#page55.tif
source=Cytori_Release_of_Security_Interest#page58.tif source=Cytori_Release_of_Security_Interest#page59.tif source=Cytori_Release_of_Security_Interest#page60.tif source=Cytori_Release_of_Security_Interest#page61.tif source=Cytori_Release_of_Security_Interest#page62.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page64.tif source=Cytori_Release_of_Security_Interest#page65.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page67.tif source=Cytori_Release_of_Security_Interest#page69.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page72.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page74.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page79.tif source=Cytori_Release_of_Security_Interest#page79.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page89.tif	source=Cytori_Release_of_Security_Interest#page56.tif
source=Cytori_Release_of_Security_Interest#page59.tif source=Cytori_Release_of_Security_Interest#page60.tif source=Cytori_Release_of_Security_Interest#page61.tif source=Cytori_Release_of_Security_Interest#page62.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page64.tif source=Cytori_Release_of_Security_Interest#page65.tif source=Cytori_Release_of_Security_Interest#page65.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page67.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page72.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page74.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page79.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page89.tif	source=Cytori_Release_of_Security_Interest#page57.tif
source=Cytori_Release_of_Security_Interest#page60.tif source=Cytori_Release_of_Security_Interest#page61.tif source=Cytori_Release_of_Security_Interest#page62.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page64.tif source=Cytori_Release_of_Security_Interest#page65.tif source=Cytori_Release_of_Security_Interest#page65.tif source=Cytori_Release_of_Security_Interest#page67.tif source=Cytori_Release_of_Security_Interest#page68.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page74.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page79.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif	source=Cytori_Release_of_Security_Interest#page58.tif
source=Cytori_Release_of_Security_Interest#page61.tif source=Cytori_Release_of_Security_Interest#page62.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page64.tif source=Cytori_Release_of_Security_Interest#page65.tif source=Cytori_Release_of_Security_Interest#page65.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page67.tif source=Cytori_Release_of_Security_Interest#page69.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page72.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page74.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page79.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif	source=Cytori_Release_of_Security_Interest#page59.tif
source=Cytori_Release_of_Security_Interest#page62.tif source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page64.tif source=Cytori_Release_of_Security_Interest#page65.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page67.tif source=Cytori_Release_of_Security_Interest#page69.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page72.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page74.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page79.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif	source=Cytori_Release_of_Security_Interest#page60.tif
source=Cytori_Release_of_Security_Interest#page63.tif source=Cytori_Release_of_Security_Interest#page64.tif source=Cytori_Release_of_Security_Interest#page65.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page67.tif source=Cytori_Release_of_Security_Interest#page68.tif source=Cytori_Release_of_Security_Interest#page69.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page72.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page74.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page79.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif	source=Cytori_Release_of_Security_Interest#page61.tif
source=Cytori_Release_of_Security_Interest#page64.tif source=Cytori_Release_of_Security_Interest#page65.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page67.tif source=Cytori_Release_of_Security_Interest#page68.tif source=Cytori_Release_of_Security_Interest#page69.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page72.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page74.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page79.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page89.tif	source=Cytori_Release_of_Security_Interest#page62.tif
source=Cytori_Release_of_Security_Interest#page65.tif source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page67.tif source=Cytori_Release_of_Security_Interest#page68.tif source=Cytori_Release_of_Security_Interest#page69.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page72.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page74.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page79.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page89.tif	source=Cytori_Release_of_Security_Interest#page63.tif
source=Cytori_Release_of_Security_Interest#page66.tif source=Cytori_Release_of_Security_Interest#page67.tif source=Cytori_Release_of_Security_Interest#page68.tif source=Cytori_Release_of_Security_Interest#page69.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page74.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page79.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page89.tif	source=Cytori_Release_of_Security_Interest#page64.tif
source=Cytori_Release_of_Security_Interest#page67.tif source=Cytori_Release_of_Security_Interest#page68.tif source=Cytori_Release_of_Security_Interest#page69.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page72.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page74.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page79.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif	source=Cytori_Release_of_Security_Interest#page65.tif
source=Cytori_Release_of_Security_Interest#page68.tif source=Cytori_Release_of_Security_Interest#page69.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page72.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page74.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page79.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif	source=Cytori_Release_of_Security_Interest#page66.tif
source=Cytori_Release_of_Security_Interest#page69.tif source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page72.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page74.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page79.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif	source=Cytori_Release_of_Security_Interest#page67.tif
source=Cytori_Release_of_Security_Interest#page70.tif source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page72.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page74.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif	source=Cytori_Release_of_Security_Interest#page68.tif
source=Cytori_Release_of_Security_Interest#page71.tif source=Cytori_Release_of_Security_Interest#page72.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page74.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif	source=Cytori_Release_of_Security_Interest#page69.tif
source=Cytori_Release_of_Security_Interest#page72.tif source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page74.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif	source=Cytori_Release_of_Security_Interest#page70.tif
source=Cytori_Release_of_Security_Interest#page73.tif source=Cytori_Release_of_Security_Interest#page74.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page79.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif	source=Cytori_Release_of_Security_Interest#page71.tif
source=Cytori_Release_of_Security_Interest#page74.tif source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page79.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif	source=Cytori_Release_of_Security_Interest#page72.tif
source=Cytori_Release_of_Security_Interest#page75.tif source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif	source=Cytori_Release_of_Security_Interest#page73.tif
source=Cytori_Release_of_Security_Interest#page76.tif source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page79.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif	source=Cytori_Release_of_Security_Interest#page74.tif
source=Cytori_Release_of_Security_Interest#page77.tif source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page89.tif	source=Cytori_Release_of_Security_Interest#page75.tif
source=Cytori_Release_of_Security_Interest#page78.tif source=Cytori_Release_of_Security_Interest#page79.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page89.tif	source=Cytori_Release_of_Security_Interest#page76.tif
source=Cytori_Release_of_Security_Interest#page79.tif source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page89.tif	source=Cytori_Release_of_Security_Interest#page77.tif
source=Cytori_Release_of_Security_Interest#page80.tif source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page89.tif	source=Cytori_Release_of_Security_Interest#page78.tif
source=Cytori_Release_of_Security_Interest#page81.tif source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page89.tif	source=Cytori_Release_of_Security_Interest#page79.tif
source=Cytori_Release_of_Security_Interest#page82.tif source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page89.tif	
source=Cytori_Release_of_Security_Interest#page83.tif source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page89.tif	. – –
source=Cytori_Release_of_Security_Interest#page84.tif source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page89.tif	source=Cytori_Release_of_Security_Interest#page82.tif
source=Cytori_Release_of_Security_Interest#page85.tif source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page89.tif	
source=Cytori_Release_of_Security_Interest#page86.tif source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page89.tif	. – –
source=Cytori_Release_of_Security_Interest#page87.tif source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page89.tif	. – –
source=Cytori_Release_of_Security_Interest#page88.tif source=Cytori_Release_of_Security_Interest#page89.tif	. – –
source=Cytori_Release_of_Security_Interest#page89.tif	
· – – · · · ·	. – –
source=Cytori_Release_of_Security_Interest#page90.tif	. – –
	source=Cytori_Release_of_Security_Interest#page90.tif



RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY

This RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY, dated as of <u>April 23, 2019</u> ("<u>Release</u>"), is executed by OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314, as collateral agent (in such capacity, "<u>Collateral Agent</u>"), in favor of CYTORI THERAPEUTICS, INC., a Delaware corporation with offices located at 3020 Callan Road, San Diego, California 92121 ("<u>Grantor</u>"), as follows:

WITNESSETH

WHEREAS, pursuant to that certain Intellectual Property Security Agreement between Collateral Agent and Grantor, dated as of September 20, 2017 ("Security Agreement"), the Grantor granted to the Collateral Agent a security interest in and to certain collateral;

WHEREAS, the Security Agreement was recorded with the Patent Division of the United States Patent and Trademark Office on September 22, 2017, at Reel 043952/Frame 0150;

WHEREAS, the Security Agreement was recorded with the Trademark Division of the United States Patent and Trademark Office on September 21, 2017, at Reel 006158/Frame 0740;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Collateral Agent hereby agrees as follows:

- 1. The Collateral Agent hereby releases, discharges, cancels and terminates its security interest in and continuing lien on Grantor's strictly on the intellectual property set forth on Schedule A attached hereto and any other intellectual property that constitutes Purchased Assets as defined in the Purchase Agreement (as defined below and without any changes to the definition of Purchased Assets made after the date hereof), and re-assigns, re-transfers and re-conveys to Grantor any and all right, title or interest the Collateral Agent may have in and to strictly the Grantor's intellectual property listed on Schedule A and any other intellectual property that constitutes Purchased Assets as defined in the Purchase Agreement (as defined below) and without any changes to such definition made after the date hereof.
- 2. The Collateral Agent agrees to execute and deliver such further instruments and take or cause to be taken such other or further action as Grantor may reasonably request, in order to perfect, confirm or evidence such release, at the sole cost and expense of the Grantor.
- 3. The Collateral Agent represents and warrants that it has the full power and authority to execute this Release.
- 4. Nothing herein constitutes or is meant to constitute a release of Collateral Agent's lien on and security interest in any proceeds from the sale of the aforementioned intellectual property paid or payable to Grantor under the terms of the Asset And Equity Purchase Agreement dated as of March 29, 2019, by and among Grantor, Lorem Vascular Pte. Ltd., a company incorporated in Singapore, and with respect to Section 6.06 only, Cytori Therapeutics, k.k., a kabushiki kaisha

1

ACTIVE 43071750v2

organized under the laws of Japan (the "<u>Purchase Agreement</u>"), which lien and security interest shall continue in accordance with the terms of the terms of that certain Loan and Security Agreement, dated May 29, 2015, by and among Grantor and Collateral Agent and other lenders party thereto from time, as amended from time to time.

5. The Collateral Agent authorizes and requests the Patent and Trademark Divisions of the United States Patent and Trademark Office, and any other appropriate domestic and foreign authorities as may be necessary or desired by Grantor to evidence this Release.

[Signature Page follows]

2

IN WITNESS WHEREOF, the Collateral Agent, by its duly authorized officer, has executed this Release of Security Interest in Intellectual Property as of the date first written above.

OXFO	RD FINANCE LLC, as Collateral Agen
By:	
Name:	Joshua Friedman
Title:	Vice President

SCHEDULE A

PATENTS

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING	US	Closed	60/462911	4/15/2003			
ADIPOSE TISSUE-							
DERIVED CELLS IN							
THE TREATMENT OF							
CARDIOVASCULAR							
CONDITIONS							
METHODS OF USING	AU	Issued	2004213858	2/20/2004	2004213858	5/7/2009	2/20/2024
ADIPOSE TISSUE-							
DERIVED CELLS IN							
THE TREATMENT OF							
CARDIOVASCULAR							
CONDITIONS							
METHODS OF USING	AU	Issued	4713403.6	2/20/2004	1599575	9/14/2011	2/20/2024
ADIPOSE TISSUE-							
DERIVED CELLS IN							
THE TREATMENT OF							
CARDIOVASCULAR							
CONDITIONS							
METHODS OF USING	BR	Published	PI0407694-0	2/20/2004			
ADIPOSE TISSUE-	į						
DERIVED CELLS IN							
THE TREATMENT OF							
CARDIOVASCULAR							
CONDITIONS	<u> </u>						

4

ACTIVE 43071750v2

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	CA	Issued	2516510	2/20/2004	2516510	7/10/2012	2/20/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	СН	Issued	4713403.6	2/20/2004	1599575	9/14/2011	2/20/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	CN	Issued	200480010610.4	2/20/2004	ZL 200480010610.4	12/29/2010	2/20/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	CZ	Issued	4713403.6	2/20/2004	1599575	9/14/2011	2/20/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	DE	Issued	4713403,6	2/20/2004	602004034318.8	9/14/2011	2/20/2024

ACTIVE 43071750v2

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	DE	Issued	11180767.3	2/20/2004	60 2004 050 659.1	1/11/2017	2/20/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	DK	Issued	4713403.6	2/20/2004	1599575	9/14/2011	2/20/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	EP	Issued	4713403.6	2/20/2004	1599575	9/14/2011	2/20/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	ЕР	Issued	11180767.3	2/20/2004	2422622	1/11/2017	2/20/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	ES	Issued	4713403.6	2/20/2004	1599575	9/14/2011	2/20/2024

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	FR	Issued	4713403,6	2/20/2004	1599575	9/14/2011	2/20/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	FR	Issued	11180767.3	2/20/2004	2422622	1/11/2017	2/20/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	GB	Issued	4713403,6	2/20/2004	1599575	9/14/2011	2/20/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	GB	Issued	11180767.3	2/20/2004	2422622	1/11/2017	2/20/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	НК	Issued	7106854.5	2/20/2004	HK1102085	11/4/2011	2/20/2024

ACTIVE 43071750v2

REEL: 049011 FRAME: 0361

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	IE	Issued	4713403.6	2/20/2004	1599575	9/14/2011	2/20/2024
USE OF ADIPOSE TISSUE-DERIVED CELLS IN THE PREPARATION OF A COMPOSITION FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	IL	Issued	170354	2/20/2004	170354	11/1/2011	2/20/2024
USE OF ADIPOSE TISSUE-DERIVED CELLS IN THE PREPARATION OF A COMPOSITION FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	IL.	Issued	214373	2/20/2004	214373	12/31/2014	2/20/2024
AN AUTOMATED CELL PROCESSING DEVICE FOR ISOLATING ADIPOSE-DERIVED REGENERATIVE CELLS FROM ADIPOSE TISSUE	IN	ABA Intent	2332/CHENP/ 2005	2/20/2004	230706	2/27/2009	2/20/2024

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	IT	Issued	4713403.6	2/20/2004	502011902003513	9/14/2011	2/20/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	KR	Issued	10-2005-7015336	2/20/2004	10-1310578	9/12/2013	2/20/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	KR	Abandoned	10-2012-7005073	2/20/2004			
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	MC	Issued	4713403.6	2/20/2004	1599575	9/14/2011	2/20/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	MX	Issued	PA/a/2005/009044	2/20/2004	279775	10/6/2010	2/20/2024

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	NL	Issued	4713403,6	2/20/2004	1599575	9/14/2011	2/20/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	WO	Closed	PCT/US2004/ 005117	2/20/2004			
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	RU	Issued	2005128964	2/20/2004	2372924	11/20/2009	2/20/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	SE	Issued	4713403.6	2/20/2004	1599575	9/14/2011	2/20/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	SG	Issued	200505359-0	2/20/2004	114309	4/30/2008	2/20/2024

ACTIVE 43071750v2

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	SK	Issued	4713403.6	2/20/2004	1599575	9/14/2011	2/20/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	ZA	Issued	2005/07446	2/20/2004	2005/07446	4/25/2007	2/20/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	EP	Unfiled					
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	US	Abandoned	10/316127	12/9/2002			
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	US	Issued	11/584202	10/20/2006	7687059	3/30/2010	1/13/2024

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
ADIPOSE-DERIVED REGENERATIVE CELLS FOR TREATING LIVER INJURY	US	Issued	13/725814	12/21/2012	9198937	12/1/2015	4/20/2023
ADIPOSE-DERIVED REGENERATIVE CELLS FOR TREATING LIVER INJURY	US	Abandoned	14/954584	11/30/2015			
ADIPOSE-DERIVED REGENERATIVE CELLS FOR TREATING LIVER INJURY	US	Abandoned	15/844091	12/15/2017			
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	US	Abandoned	10/783957	2/20/2004			
METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF STROKE AND RELATED DISEASES AND DISORDERS	US	Abandoned	10/884861	7/1/2004			

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
SYSTEMS AND	$ _{\mathrm{US}}$	Issued	10/884638	7/2/2004	7585670	9/8/2009	1/13/2024
METHODS FOR		100000	10,007030	772/2004	7505070	7/6/2003	1/13/2021
ISOLATING AND							
USING CLINICALLY							
SAFE ADIPOSE							
DERIVED							
REGENERATIVE							
CELLS							
SYSTEMS AND	US	Issued	12/554755	9/4/2009	8163276	4/24/2012	12/9/2022
METHODS FOR							
ISOLATING AND							
USING CLINICALLY							
SAFE ADIPOSE							
DERIVED							
REGENERATIVE							
CELLS							
METHODS OF USING	US	Abandoned	12/414582	3/30/2009			
ADIPOSE TISSUE-							
DERIVED CELLS IN							
THE TREATMENT OF							
CARDIOVASCULAR							
CONDITIONS							
SYSTEMS AND	US	Issued	10/877822	6/25/2004	7514075	4/7/2009	1/13/2024
METHODS FOR							
SEPARATING AND							
CONCENTRATING							
REGENERATIVE							
CELLS FROM TISSUE	<u> </u>						

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	US	Issued	10/871503	6/18/2004	7651684	1/26/2010	1/13/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	US	Issued	12/694103	1/26/2010	8246947	8/21/2012	12/9/2022
METHOD FOR PROCESSING AND USING ADIPOSE- DERIVED STEM CELLS	US	Issued	10/885293	7/1/2004	7595043	9/29/2009	1/13/2024
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	US	Abandoned	12/568533	9/28/2009			
METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS	US	Issued	10/884637	7/1/2004	7771716	8/10/2010	1/13/2024

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING	US	Issued	12/853110	8/9/2010	9504716	11/29/2016	12/9/2022
ADIPOSE DERIVED							
REGENERATIVE							
CELLS TO PROMOTE							
RESTORATION OF							
INTEVERTEBRAL							
DISC							
METHODS OF USING	US	Issued	10/884639	7/1/2004	8404229	3/26/2013	6/6/2026
REGENERATIVE							***************************************
CELLS IN THE							
TREATMENT OF							
RENAL DISEASES							
AND DISORDERS							
METHODS OF USING	US	Abandoned	10/885294	7/1/2004			
REGENERATIVE							
CELLS IN THE							
TREATMENT OF							
INHERITED AND							
ACQUIRED							-
DISORDERS OF THE							
BONE, BONE							
MARROW, LIVER,							
AND OTHER TISSUES							
METHODS OF USING	US	Issued	10/884860	7/1/2004	8105580	1/31/2012	12/9/2022
REGENERATIVE							
CELLS TO PROMOTE							
WOUND HEALING							

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING REGENERATIVE	US	Abandoned	10/884871	7/1/2004			
CELLS IN THE							
TREATMENT OF							
PERIPHERAL							
VASCULAR DISEASE							
AND RELATED							
DISORDERS							
METHODS OF USING	US	Abandoned	12/494211	6/29/2009			
REGENERATIVE							
CELLS IN THE							
TREATMENT OF							
PERIPHERAL							
VASCULAR DISEASE							
AND RELATED							
DISORDERS	776	т 1	10/0/2024	0/5/0011	0405004	12/25/2012	12/0/0000
METHODS OF	US	Issued	13/042334	3/7/2011	8337834	12/25/2012	12/9/2022
MAKING							
ENHANCED, AUTOLOGOUS FAT							
GRAFTS							
SYSTEMS AND	US	Issued	10/614431	7/7/2003	7473420	1/6/2009	1/13/2024
METHODS FOR		200464	207011131	177,2303	1,1,5,120	1,0,200	0,13,2321
TREATING PATIENTS							
WITH PROCESSED							
LIPOASPIRATE							
CELLS							

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	US	Issued	10/614392	7/7/2003	7501115	3/10/2009	1/13/2024
SELF-CONTAINED ADIPOSE DERIVED STEM CELL PROCESSING UNIT	US	Issued	10/614644	7/7/2003	7390484	6/24/2008	5/22/2024
AUTOLOGOUS ADIPOSE TISSUE IMPLANT WITH CONCENTRATED STEM CELLS	US	Issued	10/614648	7/7/2003	8119121	2/21/2012	12/9/2022
METHODS OF MAKING ENHANCED, AUTOLOGOUS FAT GRAFTS	US	Issued	12/886353	9/20/2010	7901672	3/8/2011	12/9/2022
METHODS OF MAKING ENHANCED, AUTOLOGOUS FAT GRAFTS	US	Issued	12/886341	9/20/2010	7887795	2/15/2011	12/9/2022
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	US	Issued	10/614643	7/7/2003	7429488	9/30/2008	1/13/2024

ACTIVE 43071750v2

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING	US	Issued	13/586735	8/15/2012	9511094	12/6/2016	7/2/2023
REGENERATIVE	03	issucu	13/360/33	0/13/2012	9311094	12/0/2010	1/2/2023
CELLS IN THE							
TREATMENT OF							
STROKE AND							
RELATED DISEASES							
AND DISORDERS							
SYSTEMS AND	US	Issued	13/452349	4/20/2012	8883499	11/11/2014	12/9/2022
METHODS FOR							
ISOLATING AND							
USING CLINICALLY							
SAFE ADIPOSE							
DERIVED							
REGENERATIVE							
CELLS							
SYSTEMS AND	US	Abandoned	14/537724	11/10/2014			
METHODS FOR							
ISOLATING AND							
USING CLINICALLY							
SAFE ADIPOSE							
DERIVED							
REGENERATIVE							
CELLS	110	Σ	14/00/00/1	10/13/3015	10110112	11/6/2019	12/0/2022
SYSTEMS FOR	US	Issued	14/880891	10/12/2015	10119113	11/6/2018	12/9/2022
ISOLATING AND							
USING CLINICALLY SAFE ADIPOSE							
DERIVED							
REGENERATIVE							
CELLS							
<u> </u>	L	1	l	l	1	<u>.l</u>	L

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING	US	Issued	13/588989	8/17/2012	8771678	7/8/2014	12/9/2022
ADIPOSE TISSUE-	103	issucu	13/300909	0/1//2012	0//10/8	//0/2014	12/9/2022
DERIVED CELLS IN							
AUGMENTING							-
1							
AUTOLOGOUS FAT							-
TRANSFER	110	A 1 1 7	15/4/02/12	2/15/2015			
METHODS OF USING	US	Abandoned	15/462643	3/17/2017			
ADIPOSE TISSUE-							***************************************
DERIVED CELLS IN							
THE TREATMENT OF	İ						
CARDIOVASCULAR							
CONDITIONS							
CELL CARRIER AND	US	Abandoned	13/598203	8/29/2012			
CELL CARRIER							-
CONTAINMENT							
DEVICES							
CONTAINING							-
REGENERATIVE							***
CELLS							
CELL CARRIER AND	US	Abandoned	15/366924	12/1/2016			
CELL CARRIER							
CONTAINMENT							
DEVICES							
CONTAINING							
REGENERATIVE							
CELLS							

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	US	Abandoned	15/833813	12/6/2017		155464	vac
METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS	US	Abandoned	15/362713	11/28/2016			
METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS	US	Abandoned	15/846950	12/19/2017			
METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS	US	Issued	14/462392	8/18/2014	9463203	10/11/2016	12/9/2022
METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF RENAL DISEASES AND DISORDERS	US	Issued	13/849900	3/25/2013	9504718	11/29/2016	12/9/2022

ACTIVE 43071750v2

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING	US	Abandoned	15/362249	11/28/2016		155000	Date
REGENERATIVE		litetineenee	13,302213	11/20/2010			
CELLS IN THE							
TREATMENT OF							
RENAL DISEASES							
AND DISORDERS							
METHODS OF USING	US	Issued	15/203684	7/6/2016	9872877	1/23/2018	12/9/2022
REGENERATIVE							
CELLS TO PROMOTE							
EPITHELIALIZATION							
OR NEODERMIS							
FORMATION							
METHODS OF USING	US	Issued	13/360022	1/27/2012	8691216	4/8/2014	12/9/2022
REGENERATIVE							
CELLS TO PROMOTE							
WOUND HEALING							
METHODS OF USING	US	Issued	14/180589	2/14/2014	9492483	11/15/2016	12/9/2022
REGENERATIVE							
CELLS TO PROMOTE							
WOUND HEALING							
METHODS OF USING	US	Issued	14/180553	2/14/2014	9511096	12/6/2016	12/9/2022
REGENERATIVE							
CELLS TO TREAT AN							
ISCHEMIC WOUND	ļ						
METHODS OF USING	US	Abandoned	15/877324	1/22/2018			
REGENERATIVE							
CELLS TO PROMOTE							
WOUND HEALING	<u> </u>						

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	US	Abandoned	13/296075	11/14/2011		20,000	
METHODS OF USING ADIPOSE-DERIVED REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	US	Issued	13/587700	8/16/2012	9480718	11/1/2016	3/16/2023
METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF ERECTILE DYSFUNCTION	US	Issued	14/567937	12/11/2014	9849149	12/26/2017	6/17/2023
METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	US	Abandoned	15/847709	12/19/2017			

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
DEVICES AND METHODS FOR MONITORING, MANAGING, AND SERVICING MEDICAL DEVICES	US	Abandoned	14/629305	2/23/2015			
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	AU	Issued	2005332046	5/25/2005	2005332046	8/29/2013	5/25/2025
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	AU	Issued	2013216683	8/16/2013	2013216683	10/6/2016	5/25/2025
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	BE	Issued	5754073.4	5/25/2005	1885382	3/2/2011	5/25/2025
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	CA	Issued	2609361	5/25/2005	2609361	11/14/2017	5/25/2025

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING	CH	Issued	5754073.4	5/25/2005	1885382	3/2/2011	5/25/2025
ADIPOSE TISSUE-	СП	Issueu	3/340/3,4	3/23/2003	1803302	3/2/2011	3/23/2023
DERIVED CELLS IN							
THE TREATMENT OF							
CARDIOVASCULAR							
CONDITIONS							
METHODS OF USING	CN	Abandoned	200580050265.1	5/25/2005			
ADIPOSE TISSUE-		110411401104	2002000000000001	3,23,2003			
DERIVED CELLS IN							
THE TREATMENT OF							
CARDIOVASCULAR							
CONDITIONS							
METHODS OF USING	CN	Abandoned	201210266229	7/27/2012			
ADIPOSE TISSUE-							
DERIVED CELLS IN							
THE TREATMENT OF							
CARDIOVASCULAR							
CONDITIONS	İ						
METHODS OF USING	CN	Closed					
ADIPOSE TISSUE-							
DERIVED CELLS IN							
THE TREATMENT OF							
CARDIOVASCULAR							
CONDITIONS		ļ					
METHODS OF USING	CZ	Issued	5754073.4	5/25/2005	1885382	3/2/2011	5/25/2025
ADIPOSE TISSUE-							
DERIVED CELLS IN							
THE TREATMENT OF							
CARDIOVASCULAR							
CONDITIONS	<u> </u>						

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	DE	Issued	5754073.4	5/25/2005	60 2005 026 724.7	3/2/2011	5/25/2025
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	DK	Issued	5754073.4	5/25/2005	1885382	3/2/2011	5/25/2025
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	EP	Issued	5754073,4	5/25/2005	1885382	3/2/2011	5/25/2025
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	EP	ABA Intent	11152868.3	5/25/2005	2465923	4/11/2018	5/25/2025
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	ES	Issued	5754073,4	5/25/2005	1885382	3/2/2011	5/25/2025

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	FR	Issued	5754073.4	5/25/2005	1885382	3/2/2011	5/25/2025
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	GB	Issued	5754073.4	5/25/2005	1885382	3/2/2011	5/25/2025
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	НК	Abandoned	9111059,6	5/25/2005			
METHOD OF CURING CARDIOVASCULAR DISEASES BY USING CELLS FROM ADIPOSE TISSUE	HK.	Abandoned	13107964.2	7/8/2013			
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	IΤ	Issued	5754073.4	5/25/2005	502011901950936	3/2/2011	5/25/2025

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	KR	Issued	10-2007-7030170	5/25/2005	10-1278437	6/18/2013	5/25/2025
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	KR	Issued	10-2013-7005581	3/4/2013	10-1400544	5/21/2014	5/25/2025
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	LU	Issued	5754073,4	5/25/2005	1885382	3/2/2011	5/25/2025
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	MC	Issued	5754073.4	5/25/2005	1885382	3/2/2011	5/25/2025
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	NL	Issued	5754073.4	5/25/2005	1885382	3/2/2011	5/25/2025

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	WO	Closed	PCT/US2005/ 018605	5/25/2005			
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	PL	Issued	5754073.4	5/25/2005	1885382	3/2/2011	5/25/2025
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	SE	Issued	5754073.4	5/25/2005	1885382	3/2/2011	5/25/2025
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	SK	Issued	5754073.4	5/25/2005	1885382	3/2/2011	5/25/2025
METHODS OF USING ADIPOSE TISSUE DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	ЕР	Closed	5754073.4	5/25/2004	1885382	3/2/2011	

ACTIVE 43071750v2

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	AT	Issued	12193602,5	11/21/2012	2617427	8/17/2016	7/1/2024
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	AU	Abandoned	2004318008	7/1/2004			
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	BE	Issued	12193602,5	11/21/2012	2617427	8/17/2016	7/1/2024
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	BR	Abandoned	PI0418662-1	7/1/2004			

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	CA	Abandoned	2560052	7/1/2004		1551011	<i>Mate.</i>
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	СН	Issued	12193602.5	11/21/2012	2617427	8/17/2016	7/1/2024
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	DE	Issued	4756624.5	7/1/2004	60 2004 044 686.6	3/26/2014	7/1/2024
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	DE	Issued	12193602.5	11/21/2012	60 2004 049 813.0	8/17/2016	7/1/2024

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	DK	Issued	12193602.5	11/21/2012	2617427	8/17/2016	7/1/2024
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	ЕР	Issued	4756624.5	7/1/2004	1743021	3/26/2014	7/1/2024
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	EP	Issued	12193602.5	11/21/2012	2617427	8/17/2016	7/1/2024
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	ES	Issued	12193602.5	11/21/2012	2617427	8/17/2016	7/1/2024

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	FI	Issued	12193602.5	11/21/2012	2617427	8/17/2016	7/1/2024
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	FR	Issued	4756624.5	7/1/2004	1743021	3/26/2014	7/1/2024
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	FR	Issued	12193602.5	11/21/2012	2617427	8/17/2016	7/1/2024
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	GB	Issued	4756624.5	7/1/2004	1743021	3/26/2014	7/1/2024

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	GB	Issued	12193602.5	11/21/2012	2617427	8/17/2016	7/1/2024
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	НК	Issued	1410074.7	1/23/2014	HK1187551	11/17/2017	7/1/2024
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	ΙΕ	Issued	4756624.5	7/1/2004	1743021	3/26/2014	7/1/2024
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	IE	Issued	12193602.5	11/21/2012	2617427	8/17/2016	7/1/2024

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	KR	Abandoned	10-2006-7021635	7/1/2004		155MCM	<i>Mate</i>
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	LU	Issued	12193602.5	11/21/2012	2617427	8/17/2016	7/1/2024
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	NL	Issued	4756624.5	7/1/2004	1743021	3/26/2014	7/1/2024
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	NL	Issued	12193602.5	11/21/2012	2617427	8/17/2016	7/1/2024

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	WO	Closed	PCT/US2004/ 021417	7/1/2004		ISSUEU	Date
CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	SE	Issued	12193602.5	11/21/2012	2617427	8/17/2016	7/1/2024
METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	BE	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024
METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	CA	Issued	2572113	7/1/2004	2572113	4/18/2017	7/1/2024
METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF STROKE AND RELATED DISEASES AND DISORDERS	СН	Issued	4777546.5	7/1/2004	1776126	5/13/2015	7/1/2024

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS	СН	Issued	4756626	7/1/2004	1778293	4/22/2015	7/1/2024
METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF RENAL DISEASES AND DISORDERS	СН	Issued	4777586.1	7/2/2004	1778834	8/25/2010	7/1/2024
METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	СН	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024
METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	CN	Abandoned	200480043510.1	7/1/2004			
USE OF REGENERATIVE CELLS FOR PROMOTING WOUND HEALING	CN	Issued	201110116176.X	7/1/2004	ZL 201110116176.X	9/17/2014	7/1/2024
METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	CZ	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING	DE	Tagasad	4777546,5	7/1/2004	60 2004 047 183.6	5/13/2015	7/1/2024
REGENERATIVE	DE	Issued	4///340,3	//1/2004	00 2004 04 / 183.0	3/13/2013	//1/2024
CELLS IN THE							
TREATMENT OF							
STROKE AND							
RELATED DISEASES							
AND DISORDERS							
METHODS OF USING	DE	Issued	4756626	7/1/2004	60 2004 047 061.9	4/22/2015	7/1/2024
REGENERATIVE	DE	ISSUEU	4/30020	//1/2004	00 2004 047 001.9	4/22/2013	//1/2024
CELLS IN THE							
TREATMENT OF							
MUSCULOSKELETAL							
DISORDERS							
METHODS OF USING	DE	Issued	4777586.1	7/2/2004	60 2004 028 876.4	8/25/2010	7/1/2024
REGENERATIVE	DL	Issued	4777360,1	77272004	00 2004 020 070,4	0/23/2010	// 1/2024
CELLS IN THE							
TREATMENT OF							
RENAL DISEASES							
AND DISORDERS							
METHODS OF USING	DE	Issued	4756623.7	7/1/2004	60 2004 031 782.9	3/9/2011	7/1/2024
REGENERATIVE		10000	1,20020,7	7,1,200	00 200 1 00 1 7 02.5	0,3,2011	// 1/202
CELLS TO PROMOTE							
WOUND HEALING							
METHODS OF USING	DK	Issued	4777586.1	7/2/2004	1778834	8/25/2010	7/1/2024
REGENERATIVE			1	, 200		1 -,, 2 - 1 -	
CELLS IN THE							
TREATMENT OF							
RENAL DISEASES							
AND DISORDERS							

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	DK	Issued	4756623,7	7/1/2004	1778833	3/9/2011	7/1/2024
SYSTEMS AND METHODS FOR ISOLATING AND USING CLINICALLY SAFE ADIPOSE DERIVED REGENERATIVE CELLS	EP	Abandoned	4756607	7/2/2004			
METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF STROKE AND RELATED DISEASES AND DISORDERS	ЕР	Issued	4777546,5	7/1/2004	1776126	5/13/2015	7/1/2024
METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS	ЕР	Issued	4756626	7/1/2004	1778293	4/22/2015	7/1/2024
METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS	EP	Published	15164538,9	4/21/2015			

ACTIVE 43071750v2

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING	EP	Issued	4777586.1	7/2/2004	1778834	8/25/2010	7/2/2024
REGENERATIVE	EF	issueu	477/360.1	//2/2004	1//0034	8/23/2010	//2/2024
CELLS IN THE							
TREATMENT OF							
RENAL DISEASES							
AND DISORDERS							
METHODS OF USING	EP	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024
REGENERATIVE							
CELLS TO PROMOTE							
WOUND HEALING							
METHODS OF USING	EP	Abandoned	10184623,6	7/1/2004			
REGENERATIVE							
CELLS TO PROMOTE							
WOUND HEALING							
METHODS OF USING	ES	Issued	4777586.1	7/2/2004	1778834	8/25/2010	7/1/2024
REGENERATIVE							
CELLS IN THE							
TREATMENT OF							
RENAL DISEASES							
AND DISORDERS		ļ					
METHODS OF USING	ES	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024
REGENERATIVE							
CELLS TO PROMOTE							
WOUND HEALING	<u> </u>						
METHODS OF USING	FR	Issued	4777546.5	7/1/2004	1776126	5/13/2015	7/1/2024
REGENERATIVE							
CELLS IN THE							
TREATMENT OF							
STROKE AND							
RELATED DISEASES							
AND DISORDERS	L	l	1				

ACTIVE 43071750v2

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING	FR	Issued	4756626	7/1/2004	1778293	4/22/2015	7/1/2024
REGENERATIVE	TX	155000	47,50020	//1/2004	1770293	4/22/2013	//1/2024
CELLS IN THE							
TREATMENT OF							
MUSCULOSKELETAL							
DISORDERS							
METHODS OF USING	FR	Issued	4777586.1	7/2/2004	1778834	8/25/2010	7/1/2024
REGENERATIVE							
CELLS IN THE							
TREATMENT OF							
RENAL DISEASES							
AND DISORDERS							
METHODS OF USING	FR	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024
REGENERATIVE							
CELLS TO PROMOTE							
WOUND HEALING	ļ						
METHODS OF USING	GB	Issued	4777546.5	7/1/2004	1776126	5/13/2015	7/1/2024
REGENERATIVE							
CELLS IN THE							
TREATMENT OF							
STROKE AND							
RELATED DISEASES							
AND DISORDERS	CD	T 1	1777.606	7/1/2004	1////0202	1/02/2015	T/1/2024
METHODS OF USING	GB	Issued	4756626	7/1/2004	1778293	4/22/2015	7/1/2024
REGENERATIVE CELLS IN THE							
TREATMENT OF							
MUSCULOSKELETAL							
DISORDERS							
DISORDERS	L	<u> </u>					

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING REGENERATIVE	GB	Issued	4777586.1	7/2/2004	1778834	8/25/2010	7/1/2024
CELLS IN THE TREATMENT OF							
RENAL DISEASES							
AND DISORDERS							
METHODS OF USING	GB	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024
REGENERATIVE							
CELLS TO PROMOTE							
WOUND HEALING							
SYSTEMS AND	HK	Confirm	7110355.1	7/2/2004			
METHODS FOR		ABA					
ISOLATING AND							
USING CLINICALLY							
SAFE ADIPOSE							
DERIVED							
REGENERATIVE							
USE OF	HK	71	12101967.3	7/1/2004	1165261	8/14/2015	7/1/2024
REGENERATIVE	HK	Issued	12101967.3	//1/2004	1105201	8/14/2015	//1/2024
CELLS FOR							
PROMOTING WOUND							
HEALING							
METHODS OF USING	IE	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024
REGENERATIVE		-22400	1.50025.7	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	1.,000	5/5/2011	., ., ., ., .,
CELLS TO PROMOTE							
WOUND HEALING							

ACTIVE 43071750v2

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
MEDICAMENT	IN	ABA Intent	442/CHENP/2007	7/1/2004	247580	4/25/2011	7/1/2024
COMPRISING	11/4	ADA IIIEII	442/CRENP/200/	//1/2004	24/360	4/23/2011	//1/2024
CONCENTRATED							
POPULATION OF							
ADIPOSE-DERIVED							
REGENERATIVE							
STEM CELLS FOR							
ADMINISTRATION							
TO WOUND SITE							
METHODS OF USING	IN	Abandoned	2231/CHENP/	7/1/2004			
REGENERATIVE			2011	1,72,200			
CELLS TO PROMOTE							
WOUND HEALING							
METHODS OF USING	IT	Issued	4756623,7	7/1/2004	502011901951983	3/9/2011	7/1/2024
REGENERATIVE							
CELLS TO PROMOTE							
WOUND HEALING							
METHODS OF USING	KR	Issued	10-2007-7002519	7/1/2004	10-1197909	10/30/2012	7/1/2024
REGENERATIVE							
CELLS TO PROMOTE							
WOUND HEALING							
METHODS OF USING	LU	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024
REGENERATIVE							
CELLS TO PROMOTE							
WOUND HEALING							
METHODS OF USING	MC	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024
REGENERATIVE							
CELLS TO PROMOTE							
WOUND HEALING	L			<u> </u>		<u> </u>	

Title of Invention	Country	Status	Application No.	Filing	Patent No.	Date	Expiration
AESTIONS OF HEDIC	NT.	T1	47775AC S	Date	1776106	Issued	Date
METHODS OF USING REGENERATIVE	NL	Issued	4777546.5	7/1/2004	1776126	5/13/2015	7/1/2024
CELLS IN THE							
TREATMENT OF							
STROKE AND							
RELATED DISEASES							
AND DISORDERS							
METHODS OF USING	NL	Issued	4756626	7/1/2004	1778293	4/22/2015	7/1/2024
REGENERATIVE	INL	Issueu	4/30020	//1/2004	1//0293	4/22/2013	//1/2024
CELLS IN THE							
TREATMENT OF							
MUSCULOSKELETAL							
DISORDERS							
METHODS OF USING	NL	Issued	4777586.1	7/2/2004	1778834	8/25/2010	7/1/2024
REGENERATIVE	INL	155000	4777360,1	//2/2004	1776654	0/23/2010	//1/2024
CELLS IN THE							
TREATMENT OF							
RENAL DISEASES							
AND DISORDERS							
METHODS OF USING	T _{NL}	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024
REGENERATIVE	1	100000	1750025.7	771,2001	1770033	3,7,2011	// 1/2021
CELLS TO PROMOTE							
WOUND HEALING							
SYSTEMS AND	l wo	Closed	PCT/US2004/	7/2/2004			<u> </u>
METHODS FOR			021391	.,_,_,			
ISOLATING AND							
USING CLINICALLY							
SAFE ADIPOSE							
DERIVED							
REGENERATIVE							
CELLS							

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
TREATING DISORDERS BY ADMINISTERING REGENERATIVE CELLS	WO	Closed	PCT/US2004/ 021418	7/1/2004		188000	Pare
METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF STROKE AND RELATED DISEASES AND DISORDERS	WO	Closed	PCT/US2004/ 021483	7/1/2004			
METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS	WO	Closed	PCT/US2004/ 021419	7/1/2004			
METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF RENAL DISEASES AND DISORDERS	WO	Closed	PCT/US2004/ 021549	7/1/2004			
METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	WO	Closed	PCT/US2004/ 021415	7/1/2004			

Title of Invention	Country	Status	Application No.	Filing	Patent No.	Date	Expiration
	ļ			Date		Issued	Date
METHODS OF USING	PL	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024
REGENERATIVE							
CELLS TO PROMOTE							
WOUND HEALING	ļ						
METHODS OF USING	SE	Issued	4777546.5	7/1/2004	1776126	5/13/2015	7/1/2024
REGENERATIVE							
CELLS IN THE							
TREATMENT OF							
STROKE AND							
RELATED DISEASES							
AND DISORDERS							
METHODS OF USING	SE	Issued	4756626	7/1/2004	1778293	4/22/2015	7/1/2024
REGENERATIVE							
CELLS IN THE							
TREATMENT OF							
MUSCULOSKELETAL							
DISORDERS							
METHODS OF USING	SE	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024
REGENERATIVE							
CELLS TO PROMOTE							
WOUND HEALING							
METHODS OF USING	SK	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024
REGENERATIVE							
CELLS TO PROMOTE							
WOUND HEALING							
SYSTEMS AND	AU	Issued	2002357135	12/9/2002	2002357135	1/8/2009	12/9/2022
METHODS FOR							
TREATING PATIENTS							
WITH PROCESSED							
LIPOASPIRATE							
CELLS							

ACTIVE 43071750v2

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	BR	Abandoned	PI0214772-6	12/9/2002			11/1/2017
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	BR	Abandoned	BR 12 2017 017694 3	8/17/2017			
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	CA	Issued	2469370	12/9/2002	2469370	7/8/2014	12/9/2022
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	CA	Abandoned	2849201	4/17/2014			
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	СН	Issued	2805565,5	12/9/2002	1572071	10/3/2018	12/9/2022

ACTIVE 43071750v2

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	CN	Issued	2827968.9	12/9/2002	ZL02827968.9	5/5/2010	12/9/2022
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	DE	Issued	2805565,5	12/9/2002	602 49 631.4	10/3/2018	12/9/2022
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	EP	Issued	2805565,5	12/9/2002	1572071	10/3/2018	12/9/2022
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	ЕР	Abandoned	10183690,6	12/9/2002			
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	EP	ABA Intent	10183737.5	12/9/2002			

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	FR	Issued	2805565,5	12/9/2002	1572071	10/3/2018	12/9/2022
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	GB	Issued	2805565.5	12/9/2002	1572071	10/3/2018	12/9/2022
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	НК	Issued	5110006,6	12/9/2002	HK1078009	6/30/2011	12/9/2022
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	KR	Issued	10-2004-7008785	12/9/2002	10-0811995	3/3/2008	12/9/2022
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	WO	Closed	PCT/US2002/ 039465	12/9/2002			

ACTIVE 43071750v2

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	AT	Issued	7124088.1	12/9/2002	1921133	5/20/2015	12/9/2022
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	BE	Issued	7124088.1	12/9/2002	1921133	5/20/2015	12/9/2022
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	СН	Issued	7124088.1	12/9/2002	1921133	5/20/2015	12/9/2022
A METHOD OF MAKING A SOFT TISSUE FILTER AND A METHOD OF MAKING AN ADIPOSE TISSUE IMPLANT	CN	Issued	201010105630.7	12/9/2002	2461773	4/19/2017	12/9/2022
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	DE	Issued	7124088.1	12/9/2002	602 47 199.0	5/20/2015	12/9/2022

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	DK	Issued	7124088.1	12/9/2002	1921133	5/20/2015	12/9/2022
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	EP	Issued	7124088.1	12/9/2002	1921133	5/20/2015	12/9/2022
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	ES	Issued	7124088.1	12/9/2002	1921133	5/20/2015	12/9/2022
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	FI	Issued	7124088.1	12/9/2002	1921133	5/20/2015	12/9/2022
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	FR	Issued	7124088,1	12/9/2002	1921133	5/20/2015	12/9/2022

ACTIVE 43071750v2

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	GB	Issued	7124088,1	12/9/2002	1921133	5/20/2015	12/9/2022
A METHOD OF MAKING A SOFT TISSUE FILTER AND A METHOD OF MAKING AN ADIPOSE TISSUE IMPLANT	нк	Issued	11105504.5	12/9/2002	HK1153382	3/16/2018	12/9/2022
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	IE	Issued	7124088,1	12/9/2002	1921133	5/20/2015	12/9/2022
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	KR	Issued	10-2007-7018245	12/9/2002	10-0930139	11/27/2009	12/9/2022
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	KR	Issued	10-2008-7027860	12/9/2002	10-1083454	11/8/2011	12/9/2022

ACTIVE 43071750v2

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	KR	Issued	10-2010-7002719	12/9/2002	10-1150666	5/21/2012	12/9/2022
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	KR	Abandoned	10-2011-7028207	12/9/2002			
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	LU	Issued	7124088.1	12/9/2002	1921133	5/20/2015	12/9/2022
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	NL	Issued	7124088.1	12/9/2002	1921133	5/20/2015	12/9/2022
SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	SE	Issued	7124088.1	12/9/2002	1921133	5/20/2015	12/9/2022

Title of Invention	Country	Status	Application No.	Filing	Patent No.	Date	Expiration
CALCETTA ACLANTS	TIG	ent 1	CO (40 C 1 C 77	Date		Issued	Date
SYSTEMS AND	US	Closed	60/496467	8/20/2003			
METHODS FOR							
SEPARATING CELLS							
FROM ADIPOSE							
TISSUE						ļ	
SYSTEMS AND	AU	Issued	2004260937	6/25/2004	2004260937	8/26/2010	6/25/2024
METHODS FOR							
SEPARATING AND							
CONCENTRATING							
REGENERATIVE							
CELLS FROM TISSUE							
SYSTEMS AND	BR	Pending	PI0411798-0	6/25/2004			
METHODS FOR							
SEPARATING AND							
CONCENTRATING							
REGENERATIVE							
CELLS FROM TISSUE							
SYSTEMS AND	CA	Abandoned	2530630	6/25/2004			
METHODS FOR							
SEPARATING AND							
CONCENTRATING							
REGENERATIVE							
CELLS FROM TISSUE							
SYSTEMS AND	CN	Issued	200480024624.1	6/25/2004	ZL2004800246241	4/25/2012	6/25/2024
METHODS FOR							
SEPARATING AND							
CONCENTRATING							
REGENERATIVE							
CELLS FROM TISSUE							

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
SYSTEMS AND	EP	Abandoned	4777155.5	6/25/2004		issueu	Date
METHODS FOR	EF	Abandoned	4///133,3	0/23/2004			
SEPARATING AND							
CONCENTRATING							
REGENERATIVE							
CELLS FROM TISSUE							
SYSTEMS AND	EP	Abandoned	11156001.7	6/25/2004	2380970	12/20/2017	6/25/2024
METHODS FOR	1	Abandoned	11150001.7	0/25/2004	2300370	12/20/2017	0/23/2024
SEPARATING AND							
CONCENTRATING							
REGENERATIVE							
CELLS FROM TISSUE							
SYSTEMS AND	HK	Issued	7103532.2	6/25/2004	HK1096424	2/1/2013	6/25/2024
METHODS FOR		15564	, 100101,1	0,20,200	11111070.11.	2, 1, 2 5 15	0,22,202
SEPARATING AND							
CONCENTRATING							
REGENERATIVE							
CELLS FROM TISSUE							
SYSTEMS AND	IL	Issued	172800	6/25/2004	172800	2/1/2011	6/25/2024
METHODS FOR							
SEPARATING AND							
CONCENTRATING							
REGENERATIVE							
CELLS FROM TISSUE							
SYSTEMS AND	IN	ABA Intent	302/CHENP/2006	6/25/2004	229529	2/18/2009	6/25/2024
METHODS FOR							
SEPARATING AND							
CONCENTRATING							
REGENERATIVE							
CELLS FROM TISSUE							

Title of Invention	Country	Status	Application No.	Filing	Patent No.	Date	Expiration
L		ļ	<u> </u>	Date	ļ	Issued	Date
SYSTEMS AND	KR	Issued	10-2005-7024986	6/25/2004	10-1127305	3/8/2012	6/25/2024
METHODS FOR							***************************************
SEPARATING AND							
CONCENTRATING							
REGENERATIVE							***************************************
CELLS FROM TISSUE							
SYSTEMS AND	MX	Issued	PA/a/2006/000062	6/25/2004	270348	9/23/2009	6/25/2024
METHODS FOR							
SEPARATING AND							
CONCENTRATING							***************************************
REGENERATIVE							
CELLS FROM TISSUE							
SYSTEMS AND	WO	Closed	PCT/US2004/0205	6/25/2004			
METHODS FOR			94				
SEPARATING AND							
CONCENTRATING							
REGENERATIVE							
CELLS FROM TISSUE							
SYSTEMS AND	SG	Issued	200508560-0	6/25/2004	118683	12/31/2007	6/25/2024
METHODS FOR							7
SEPARATING AND							
CONCENTRATING							
REGENERATIVE							
CELLS FROM TISSUE							

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING	US	Closed	60/503589	9/17/2003		133404	Date
ADIPOSE TISSUE-		Clesca	00,00000	3,1,,2003			
DERIVED CELLS IN							
THE TREATMENT OF							
PERIPHERAL							***************************************
VASCULAR DISEASE							
AND RELATED							
CONDITIONS							***************************************
METHODS OF USING	AT	Issued	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
REGENERATIVE							
CELLS IN THE							
TREATMENT OF							
PERIPHERAL							
VASCULAR DISEASE							
AND RELATED							
DISORDERS							
METHODS OF USING	AU	Abandoned	2004280149	7/1/2004			
REGENERATIVE							
CELLS IN THE							
TREATMENT OF							***************************************
PERIPHERAL							
VASCULAR DISEASE							
AND RELATED							
DISORDERS	<u> </u>						

Title of Invention	Country	Status	Application No.	Filing	Patent No.	Date	Expiration
	L			Date		Issued	Date
METHODS OF USING	BE	Issued	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
REGENERATIVE							
CELLS IN THE							
TREATMENT OF							
PERIPHERAL							
VASCULAR DISEASE							
AND RELATED							
DISORDERS							
METHODS OF USING	BR	Abandoned	PI04144554	7/1/2004			
REGENERATIVE							
CELLS IN THE							
TREATMENT OF							
PERIPHERAL							
VASCULAR DISEASE							
AND RELATED							
DISORDERS							
METHODS OF USING	CA.	Abandoned	2539346	7/1/2004			
REGENERATIVE							
CELLS IN THE							
TREATMENT OF							
PERIPHERAL							
VASCULAR DISEASE							
AND RELATED							
DISORDERS							

Title of Invention	Country	Status	Application No.	Filing	Patent No.	Date	Expiration Date
METHODS OF USING	CH	Tagasad	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
REGENERATIVE	CH	Issued	4/30041,9	//1/2004	10/0313	4/19/2017	//1/2024
CELLS IN THE							
TREATMENT OF							
PERIPHERAL							
VASCULAR DISEASE							
AND RELATED							
DISORDERS							
METHODS OF USING	CN	Abandoned	200480033368.2	7/1/2004			
REGENERATIVE							
CELLS IN THE							
TREATMENT OF	į						
PERIPHERAL							
VASCULAR DISEASE							
AND RELATED							
DISORDERS							
METHODS OF USING	DE	Issued	4756641.9	7/1/2004	6020040511116,1	4/19/2017	7/1/2024
REGENERATIVE							
CELLS IN THE							
TREATMENT OF							
PERIPHERAL							
VASCULAR DISEASE							
AND RELATED							
DISORDERS							

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING	DK	Issued	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
REGENERATIVE				.,			., .,
CELLS IN THE							
TREATMENT OF							
PERIPHERAL							
VASCULAR DISEASE							
AND RELATED							
DISORDERS							
METHODS OF USING	EP	Issued	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
REGENERATIVE							
CELLS IN THE							
TREATMENT OF							
PERIPHERAL							
VASCULAR DISEASE							
AND RELATED							
DISORDERS							
METHODS OF USING	EP	Published	10183850,6	7/1/2004	2348103		
REGENERATIVE							
CELLS IN THE							
TREATMENT OF							
PERIPHERAL							
VASCULAR DISEASE							
AND RELATED							
DISORDERS	<u> </u>	J				<u> </u>	<u>]</u>

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING	ES	Issued	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
REGENERATIVE	ES	Issucu	4/30041,3	//1/2004	10/0313	4/19/2017	//1/2024
CELLS IN THE							
TREATMENT OF							
PERIPHERAL							
VASCULAR DISEASE							
AND RELATED							***************************************
DISORDERS							
METHODS OF USING	FI	Issued	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
REGENERATIVE	LI	Issued	4/30041.9	//1/2004	16/0313	4/19/201/	//1/2024
į ·	ĺ						
CELLS IN THE							
TREATMENT OF							
PERIPHERAL							
VASCULAR DISEASE							
AND RELATED							
DISORDERS	ļ						
METHODS OF USING	FR	Issued	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
REGENERATIVE							
CELLS IN THE							
TREATMENT OF							
PERIPHERAL							
VASCULAR DISEASE							
AND RELATED							
DISORDERS							

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING REGENERATIVE	GB	Issued	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
CELLS IN THE							
TREATMENT OF							
PERIPHERAL							
VASCULAR DISEASE							
AND RELATED							
DISORDERS							
METHODS OF USING	IE	Issued	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
REGENERATIVE							
CELLS IN THE							
TREATMENT OF							
PERIPHERAL							
VASCULAR DISEASE							
AND RELATED							
DISORDERS						ļ	
METHODS OF USING	IT	Issued	4756641.9	7/1/2004	502017000081373	4/19/2017	7/1/2024
REGENERATIVE							
CELLS IN THE							
TREATMENT OF							
PERIPHERAL NA COLL AR DISEASE							
VASCULAR DISEASE							
AND RELATED							
DISORDERS		<u> </u>					<u> </u>

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING	KR	Abandoned	10-2006-7007257	7/1/2004		ISSUEU	Date
REGENERATIVE	IXIX	Abandoned	10-2000-7007257	//1/2004			
CELLS IN THE							
TREATMENT OF							
PERIPHERAL							
VASCULAR DISEASE							
AND RELATED							
DISORDERS							
METHODS OF USING	LU	Issued	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
REGENERATIVE		Issued	4/30041.7	77172004	10/0313	4/17/2017	//1/2024
CELLS IN THE							
TREATMENT OF							
PERIPHERAL							
VASCULAR DISEASE							
AND RELATED							
DISORDERS							
METHODS OF USING	MX	Abandoned	PA/a/2006/003088	7/1/2004			
REGENERATIVE	19.123.	Asomiconed	1 75/4/2000/005050	77172004			
CELLS IN THE							
TREATMENT OF							
PERIPHERAL							
VASCULAR DISEASE							
AND RELATED							
DISORDERS							

Title of Invention	Country	Status	Application No.	Filing	Patent No.	Date	Expiration
A POTTION OF HUNDING	NT.	· +	1777.CC.11.O	Date	1.000010	Issued	Date
METHODS OF USING	NL	Issued	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
REGENERATIVE							
CELLS IN THE							
TREATMENT OF							
PERIPHERAL							
VASCULAR DISEASE							
AND RELATED							
DISORDERS							
METHODS OF USING	NO	Issued	4756641.9	7/1/2004	1670315	4/19/2017	
REGENERATIVE							
CELLS IN THE							
TREATMENT OF							
PERIPHERAL							
VASCULAR DISEASE							
AND RELATED							
DISORDERS							
METHODS OF USING	WO	Closed	PCT/US2004/	7/1/2004			
REGENERATIVE			021480				
CELLS IN THE							
TREATMENT OF							
PERIPHERAL							
VASCULAR DISEASE							
AND RELATED							
DISORDERS							

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	SG	Abandoned	200806960-1	7/1/2004		3.55304.33	<i>butt</i>
METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	SE	Issued	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	SG	Abandoned	200601759-4	7/1/2004			
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	US	Closed	60/479418	6/18/2003			

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	AU	Abandoned	2004260638	6/18/2004			
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	BR	Abandoned	PI0411621-6	6/18/2004			
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	CA	Abandoned	2529954	6/18/2004			
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	СН	Issued	4776784.3	6/18/2004	1638507	3/22/2017	6/18/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	CN	Abandoned	200480023804.8	6/18/2004			

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	DE	Issued	4776784,3	6/18/2004	602004050967,1	3/22/2017	6/18/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	DK	Issued	4776784.3	6/18/2004	1638507	3/22/2017	6/18/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	EP	Issued	4776784,3	6/18/2004	1638507	3/22/2017	6/18/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	FR	Issued	4776784.3	6/18/2004	1638507	3/22/2017	6/18/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	GB	Issued	4776784.3	6/18/2004	1638507	3/22/2017	6/18/2024

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	НК	Abandoned	6110836.1	6/18/2004		200,000	
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	KR	Issued	10-2005-7024356	6/18/2004	10-1145508	5/4/2012	6/18/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	MX	Abandoned	PA/a/2005/013967	6/18/2004			
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	NL	Issued	4776784.3	6/18/2004	1638507	3/22/2017	6/18/2024
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	WO	Closed	PCT/US2004/ 019611	6/18/2004			

Title of Invention	Country	Status	Application No.	Filing	Patent No.	Date	Expiration
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	SE	Issued	4776784,3	6/18/2004	1638507	3/22/2017	6/18/2024
SYSTEMS AND METHODS FOR MANIPULATION OF REGENERATIVE CELLS FROM ADIPOSE TISSUE	US	Abandoned	13/926854	6/25/2013			
SYSTEMS AND METHODS FOR MANIPULATION OF REGENERATIVE CELLS FROM ADIPOSE TISSUE	US	Abandoned	14/860416	9/21/2015			
SYSTEMS AND METHODS FOR MANIPULATION OF REGENERATIVE CELLS SEPARATED AND CONCENTRATED FROM ADIPOSE TISSUE	US	Abandoned	12/302787	8/12/2009			

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
SYSTEMS AND METHODS FOR MANIPULATION OF REGENERATIVE CELLS SEPARATED AND CONCENTRATED FROM ADIPOSE TISSUE	US	Closed	60/685206	5/27/2005		100000	Date
SYSTEMS AND METHODS FOR MANIPULATION OF REGENERATIVE CELLS SEPARATED AND CONCENTRATED FROM ADIPOSE TISSUE	WO	Closed	PCT/US2006/ 021017	5/30/2006			
SYSTEMS AND METHODS FOR MANIPULATION OF REGENERATIVE CELLS SEPARATED AND CONCENTRATED FROM ADIPOSE TISSUE	US	Closed	60/693323	6/22/2005			
CELL DELIVERY CATHETERS WITH DISTAL TIP HIGH FIDELITY SENSORS	US	Abandoned	12/090241	9/10/2008			

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
CELL DELIVERY	US	Closed	60/727174	10/14/2005			
CATHETERS WITH							
DISTAL TIP HIGH							
FIDELITY SENSORS	ļ			10/15/2005			
CELL DELIVERY	EP	Abandoned	6825964.7	10/16/2006			
CATHETERS WITH							
DISTAL TIP HIGH							
FIDELITY SENSORS	XX.00	Z-11 1	Demarasos	10/16/2006			
CELL DELIVERY	WO	Closed	PCT/US2006/	10/16/2006			
CATHETERS WITH			040221				
DISTAL TIP HIGH							
FIDELITY SENSORS	TIC	<u> </u>	60/520152	10/24/2005			
ADIPOSE-DERIVED CELLS FOR	US	Closed	60/730153	10/24/2005			
ARTERIOLE AND							
ARTERY							
FORMATION							
ADIPOSE-DERIVED	US	Closed	60/730127	10/24/2005			
CELL-DERIVED	05	Ciosea	00//3012/	10/24/2003			
NEOTISSUE FOR							
SOFT TISSUE							
FILLING							
ADIPOSE-DERIVED	US	Closed	60/793422	4/19/2006			
CELL-DERIVED							
NEOTISSUE FOR							
SOFT TISSUE							
FILLING							

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
ADIPOSE-DERIVED	US	Closed	60/793421	4/19/2006			
CELLS FOR							
ARTERIOLE AND							
ARTERY							
FORMATION							
METHODS OF USING	US	Issued	13/031031	2/18/2011	8784801	7/22/2014	2/18/2030
ADIPOSE TISSUE-							
DERIVED CELLS IN							
THE TREATMENT OF							
THE LYMPHATIC							
SYSTEM AND							
MALIGNANT							
DISEASE							
METHODS OF USING	US	Issued	14/336755	7/21/2014	9486484	11/8/2016	2/6/2030
ADIPOSE TISSUE-							
DERIVED CELLS IN							
THE TREATMENT OF							
THE LYMPHATIC							
SYSTEM AND							
MALIGNANT							
DISEASE	****		1.8.6.1.84.0.1	44.09.00.00			ļ
METHODS OF USING	US	Abandoned	15/345294	11/7/2016			
ADIPOSE TISSUE-							
DERIVED CELLS IN							
THE TREATMENT OF							
THE LYMPHATIC SYSTEM AND							
MALIGNANT							
DISEASE	L	<u> </u>	[<u> </u>

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date	Expiration Date
METHODS OF USING	US	Closed	60/795334	4/26/2006		Issued	Date
ADIPOSE TISSUE-	US	Ciosed	00//93334	4/20/2000			
DERIVED CELLS IN							
1							
THE TREATMENT OF							
THE LYMPHATIC							
SYSTEM AND							
MALIGNANT							
DISEASE							
METHODS OF USING	US	Closed	60/945320	6/20/2007			
ADIPOSE TISSUE-							
DERIVED CELLS IN							
THE TREATMENT OF							
THE LYMPHATIC							
SYSTEM AND							
MALIGNANT							
DISEASE							
METHODS OF USING	US	Abandoned	61/074299	6/20/2008			
ADIPOSE TISSUE-							
DERIVED CELLS IN							
THE TREATMENT OF							
THE LYMPHATIC							
SYSTEM AND							
MALIGNANT							
DISEASE							

Title of Invention	Country	Status	Application No.	Filing	Patent No.	Date	Expiration
	L			Date		Issued	Date
METHODS OF USING	US	Closed	61/090186	8/19/2008			
ADIPOSE TISSUE-							
DERIVED CELLS IN							
THE TREATMENT OF							
THE LYMPHATIC							
SYSTEM AND							
MALIGNANT							
DISEASE			D.OTT. 7-01-000/	0.000000			
METHODS OF USING	WO	Expired	PCT/US2009/	8/17/2009			
ADIPOSE TISSUE-			054055				
DERIVED CELLS IN							
THE TREATMENT OF							
THE LYMPHATIC							
SYSTEM AND							
MALIGNANT							
DISEASE	7.70						
GENERATION OF	US	Closed					
ADIPOSE TISSUE							
AND ADIPOCYTES	710	(3 3 3	10 (0 55 50 0 5	0/25/2000			-
GENERATION OF	US	Abandoned	12/375005	9/25/2009			
ADIPOSE TISSUE							
AND ADIPOCYTES	TIG	01 1	(0.0000000	T/06/2006			
GENERATION OF	US	Closed	60/833561	7/26/2006			
ADIPOSE TISSUE							
AND ADIPOCYTES	X1(C)		Demaraana.		 		
GENERATION OF	WO	Closed	PCT/US2007/	7/25/2007			
ADIPOSE TISSUE			016750				
AND ADIPOCYTES	<u> </u>		L				

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
INDIVIDUALIZED	US	Abandoned	12/188950	8/8/2008			
DOSAGE							
DETERMINATION							
FOR SAFE							
INTRAVASCULAR							
ADMINISTRATION							
OF PARTICLES							
INDIVIDUALIZED	US	Closed	60/838288	8/16/2006			
DOSAGE							
DETERMINATION							
FOR SAFE							
INTRAVASCULAR							
ADMINISTRATION							
OF PARTICLES							
INDIVIDUALIZED	US	Closed	60/955252	8/10/2007			
DOSAGE							
DETERMINATION							
FOR SAFE							
INTRAVASCULAR							
ADMINISTRATION							
OF PARTICLES	ļ						
PRESERVATION OF	US	Abandoned	10/242094	9/12/2002			
NON EMBRYONIC							
CELLS FROM NON							
HEMATOPOIETIC							
TISSUES	<u> </u>						

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
DEVICES, METHODS AND COMPOSITION FOR THE PRESERVATION AND USE OF MAMMALIAN NONEMBRYONIC STEM/PROGENITOR CELLS AND MATRIX MATERIAL FROM NONHEMATOPOIETI	US	Closed	60/322070	9/14/2001		issued	pate
PRESERVATION OF NON EMBRYONIC CELLS FROM NON HEMATOPOIETIC TISSUES	AU	Issued	2002326901	9/13/2002	2002326901	2/14/2008	9/13/2022
PRESERVATION OF NON EMBRYONIC CELLS FROM NON HEMATOPOIETIC TISSUES	CA	Abandoned	2460402	9/13/2002			
PRESERVATION OF NON EMBRYONIC CELLS FROM NON HEMATOPOIETIC TISSUES	CN	Abandoned	2822628.3	9/13/2002			

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
PRESERVATION OF NON EMBRYONIC CELLS FROM NON HEMATOPOIETIC TISSUES	EP	Published	2761654.9	9/13/2002			
PRESERVATION OF NON EMBRYONIC CELLS FROM NON HEMATOPOIETIC TISSUES	HK	Abandoned	4108806.3	9/13/2002			
PRESERVATION OF NON EMBRYONIC CELLS FROM NON HEMATOPOIETIC TISSUES	KR	Issued	10-2004-7003710	9/13/2002	10-0779812	11/20/2007	9/13/2022
PRESERVATION OF NON EMBRYONIC CELLS FROM NON HEMATOPOIETIC TISSUES	WO	Closed	PCT/US02/29207	9/13/2002			
SYSTEMS AND METHODS FOR MANIPULATION OF REGENERATIVE CELLS USING ELECTRICAL FIELDS	US	Closed	60/720060	9/23/2005			

Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
US	Abandoned	10/325728			233424	- Auto
		,				
CA	Abandoned	2470031	12/20/2002			
CN	Abandoned	02828237.X	12/20/2002			
ED	A1 1 1	2005640.0	12/20/2002		ļ	
Er	Abandoned	2803048,9	12/20/2002			
	US	US Abandoned CA Abandoned CN Abandoned	US Abandoned 10/325728 CA Abandoned 2470031 CN Abandoned 02828237.X	US Abandoned 10/325728 12/20/2002 CA Abandoned 2470031 12/20/2002 CN Abandoned 02828237.X 12/20/2002	US Abandoned 10/325728 12/20/2002 CA Abandoned 2470031 12/20/2002 CN Abandoned 02828237.X 12/20/2002	US Abandoned 10/325728 12/20/2002 Issued CA Abandoned 2470031 12/20/2002 Issued CN Abandoned 2470031 12/20/2002 Issued CN Abandoned 02828237.X 12/20/2002 Issued

Title of Invention	Country	Status	Application No.	Filing	Patent No.	Date	Expiration
				Date		Issued	Date
SYSTEMS AND	HK	Abandoned	5110647.1	12/20/2002			
METHODS FOR							
TREATING PATIENTS							
WITH COLLAGEN-							
RICH MATERIAL							***************************************
EXTRACTED FROM							
ADIPOSE TISSUE							
SYSTEMS AND	WO	Closed	PCT/US02/40921	12/20/2002			
METHODS FOR							***************************************
TREATING PATIENTS							
WITH COLLAGEN-							
RICH MATERIAL							
EXTRACTED FROM							
ADIPOSE TISSUE							
METHODS OF USING	US	Closed	60/449279	2/20/2003			
ADIPOSETISSUE-							-
DERIVED CELLS IN							
THE TREATMENT OF							***************************************
CARDIOVASCULAR							
CONDITIONS							
RESORBABLE							
RADIOPAQUE							
MARKERS							
DEVICES AND	US	Closed	60/642954	1/10/2005			
METHODS FOR							
INDUCING TISSUE							
FORMATION AND							
BILLING A USER OF							
THE DEVICES AND							
METHODS	l	<u> </u>					

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
SYSTEMS AND	US	Closed	60/482820	6/25/2003			
METHODS FOR							
SEPARATING CELLS							
FROM ADIPOSE							
TISSUE							
CELL-LOADED	US	Closed	60/639013	12/22/2004			
PROSTHESES FOR							
REGENERATIVE							
INTRALUMINAL							
APPLICATIONS	ļ						
CELL-LOADED	EP	Abandoned					
PROSTHESES FOR							
REGENERATIVE							
INTRALUMINAL							
APPLICATIONS							
CELL-LOADED	WO	Abandoned	PCT/US2005/	12/22/2005			
PROSTHESES FOR			046926				
REGENERATIVE							
INTRALUMINAL							
APPLICATIONS							
INDIVIDUALIZED	US	Closed	60/858161	11/10/2006			
DOSAGE	İ						
DETERMINATION							
FOR LOCAL							
ADMINISTRATION							
OF THERAPEUTICS							
PARTICLES	L						

Title of Invention	Country	Status	Application No.	Filing	Patent No.	Date	Expiration
TATESTALLA LIGHTS	77/0	61 1	DOTEGIGAGOS/	Date		Issued	Date
INDIVIDUALIZED	WO	Closed	PCT/US2007/	11/9/2007			
DOSAGE			023646				
DETERMINATION							
FOR LOCAL							
ADMINISTRATION							
OF THERAPEUTIC							
PARTICLES	770	01 1	(0/002402	2/26/2007		<u> </u>	
ALTERNATING	US	Closed	60/903485	2/26/2007			
CONNECTION							
ROTATION SEAL							
APPARATUS	THO	43 1 3	DODG IGAGOO!	2/27/2000			
ALTERNATING	WO	Abandoned	PCT/US2008/	2/25/2008			
CONNECTION			054921				
ROTATION SEAL							
APPARATUS	rra	41 7 7	11/220020	0/15/0005			ļ
METHODS FOR	US	Abandoned	11/229028	9/15/2005			
MAKING AND USING							
COMPOSITES,							
POLYMER							
SCAFFOLDS, AND							
COMPOSITE							
SCAFFOLDS			50 (54 74 40	0/20/2004		ļ	
METHODS FOR	US	Closed	60/615140	9/30/2004			
MAKING AND USING							
COMPOSITES,							
POLYMER							
SCAFFOLDS, AND							
COMPOSITE							
SCAFFOLDS						<u> </u>	

Title of Invention	Country	Status	Application No.	Filing	Patent No.	Date	Expiration
<u> </u>				Date		Issued	Date
METHODS FOR	EP	Abandoned	5814850,3	9/15/2005			
MAKING AND USING							
COMPOSITES,							
POLYMER							
SCAFFOLDS, AND							
COMPOSITE							
SCAFFOLDS	ļ						
METHODS FOR	WO	Closed	PCT/US2005/	9/15/2005			
MAKING AND USING			033329				
COMPOSITES,							
POLYMER							
SCAFFOLDS, AND							
COMPOSITE							
SCAFFOLDS							
SYRINGE SYSTEM	US	Abandoned	12/766768	4/23/2010			
FOR CONTROLLED							
DELIVERY OR							***************************************
REMOVAL OF							
MATERIAL							
SYRINGE SYSTEM	US	Abandoned	13/450262	4/18/2012			
FOR CONTROLLED							***
DELIVERY OR							
REMOVAL OF							
MATERIAL	<u> </u>						
SYRINGE SYSTEM	US	Closed	60/983054	10/26/2007			
FOR CONTROLLLED							
DELIVERY OR							
REMOVAL OF							
MATERIAL							

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
SYRINGE SYSTEM FOR CONTROLLED DELIVERY OR REMOVAL OF MATERIAL	US	Closed	60/987738	11/13/2007			
SYRINGE SYSTEM FOR CONTROLLED DELIVERY OR REMOVAL OF MATERIAL	IN	Abandoned	3177/DELNP/ 2010	10/23/2008			
SYRINGE SYSTEM FOR CONTROLLED DELIVERY OR REMOVAL OF MATERIAL	WO	Closed	PCT/US2008/ 081012	10/23/2008			
METHODS OF INHIBITING TUMOR DEVELOPMENT USING ADIPOSE- DERIVED REGENERATIVE CELLS	US	Closed	61/013442	12/13/2007			
METHODS OF INHIBITING TUMOR DEVELOPMENT USING ADIPOSE- DERIVED REGENERATIVE CELLS	WO	Closed	PCT/US2008/ 086470	12/11/2008			

Title of Invention	Country	Status	Application No.	Filing	Patent No.	Date	Expiration
				Date		Issued	Date
METHODS OF	US	Closed					
TREATING							
PANCREATITIS							
USING ADIPOSE-							
DERIVED							
REGENERATIVE							
CELLS						ļ	<u> </u>
USE OF HUMAN	US	Closed					
TISSUE FOR THE							
PURPOSE AS A CELL							
TRAP AS A METHOD							***************************************
OF CONCENTRATING							
THE CELL DURING							
PROCESSING							
USE ADIPOSE	US	Abandoned	13/279090	10/21/2011			
TISSUE-DERIVED							
REGENERATIVE							
CELLS IN THE							***
MODULATION OF							
INFLAMMATION IN							
THE PANCREAS AND							
IN THE KIDNEY							ļ
USE ADIPOSE	US	Abandoned	13/720829	12/19/2012			***************************************
TISSUE-DERIVED							
REGENERATIVE							
CELLS IN THE							
MODULATION OF							
INFLAMMATION IN							
THE PANCREAS AND							
IN THE KIDNEY	L	<u> </u>			<u></u>	<u></u>	L

Title of Invention	Country	Status	Application No.	Filing	Patent No.	Date	Expiration
TIGE ADIDOCE	EP	41	107156416	Date 4/22/2010		Issued	Date
USE ADIPOSE TISSUE-DERIVED	EP	Abandoned	10715641.6	4/23/2010			
REGENERATIVE							
CELLS IN THE							
MODULATION OF							
INFLAMMATION IN							
THE PANCREAS AND							
IN THE KIDNEY							
METHODS OF USING	US	Expired	61/172152	4/23/2009			4/23/2010
ADIPOSE TISSUE-	03	Lapited	01/1/2132	4/23/2009			7/23/2010
DERIVED CELLS IN							
THE MODULATION							
OF INFLAMMATION							
USE ADIPOSE	WO	Expired	PCT/US2010/	4/23/2010			
TISSUE-DERIVED			032275	1,20,2010			
REGENERATIVE							
CELLS IN THE							
MODULATION OF							
INFLAMMATION IN							
THE PANCREAS AND							
IN THE KIDNEY							
SYSTEMS, METHODS	US	Transferred	12/771985	4/30/2010			
AND COMPOSITIONS							
FOR OPTIMIZING							
TISSUE AND CELL							
ENRICHED GRAFTS							
SYSTEMS, METHODS	AU	Transferred	2010242780	4/30/2010			
AND COMPOSITIONS							
FOR OPTIMIZING							
TISSUE AND CELL							
ENRICHED GRAFTS							

ACTIVE 43071750v2

PATENT REEL: 049011 FRAME: 0438

Title of Invention	Country	Status	Application No.	Filing	Patent No.	Date	Expiration
CATCHER AC A MERCHANIC	ממ	70	DI1000001 (Date 4/20/2010		Issued	Date
SYSTEMS, METHODS	BR	Transferred	PI1009981-6	4/30/2010			
AND COMPOSITIONS							-
FOR OPTIMIZING							
TISSUE AND CELL							
ENRICHED GRAFTS							
SYSTEMS, METHODS	US	Transferred					
AND COMPOSITIONS							***************************************
FOR OPTIMIZING							***
TISSUE AND CELL							
ENRICHED GRAFTS							
SYSTEMS, METHODS	CA	Transferred	2760574	4/30/2010			-
AND COMPOSITIONS							***************************************
FOR OPTIMIZING							
TISSUE AND CELL							-
ENRICHED GRAFTS							
SYSTEMS, METHODS	CN	Transferred	201080029915.5	4/30/2010			
AND COMPOSITIONS							
FOR OPTIMIZING							***************************************
TISSUE AND CELL							
ENRICHED GRAFTS							-
SYSTEMS, METHODS	EP	Transferred	10770460,3	4/30/2010			
AND COMPOSITIONS							***************************************
FOR OPTIMIZING							
TISSUE AND CELL							***************************************
ENRICHED GRAFTS							
SYSTEMS, METHODS	HK	Transferred	12109852,4	10/8/2012			
AND COMPOSITIONS							***************************************
FOR OPTIMIZING							
TISSUE AND CELL							
ENRICHED GRAFTS							

Title of Invention	Country	Status	Application No.	Filing	Patent No.	Date	Expiration
CATCHERAC ARTERIOTS	TAI	75	9001/DEX ND/	Date 4/20/2010		Issued	Date
SYSTEMS, METHODS	IN	Transferred	8801/DELNP/	4/30/2010			
AND COMPOSITIONS			2011				
FOR OPTIMIZING							
TISSUE AND CELL							
ENRICHED GRAFTS			10 0011 7000501	1/20/2010			-
SYSTEMS, METHODS	KR	Transferred	10-2011-7028621	4/30/2010			
AND COMPOSITIONS							
FOR OPTIMIZING							-
TISSUE AND CELL							
ENRICHED GRAFTS				<u> </u>			<u> </u>
SYSTEMS, METHODS	MX	Transferred	MX/a/2011/	4/30/2010			
AND COMPOSITIONS			011402				
FOR OPTIMIZING							
TISSUE AND CELL							
ENRICHED GRAFTS							
SYSTEMS, METHODS	US	Transferred	61/174860	5/1/2009			5/1/2010
AND COMPOSITIONS							***************************************
FOR OPTIMIZING							
TISSUE AND CELL							
GRAFTS							
SYSTEMS, METHODS	WO	Transferred	PCT/US2010/	4/30/2010			
AND COMPOSITIONS			033283				
FOR OPTIMIZING							
TISSUE AND CELL							
ENRICHED GRAFTS							
SYSTEMS, METHODS	ZA	Transferred	2011/8756	4/30/2010	2011/8756	2/26/2014	4/30/2030
AND COMPOSITIONS							
FOR OPTIMIZING							
TISSUE AND CELL							
ENRICHED GRAFTS							

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
ADIPOSE DERIVED	US	Closed					
STEM CELL							
ISOLATION DEVICE							
AN APPARATUS FOR	US	Closed					
ISOLATING STEM							
CELLS FROM							
ADIPOSE DERIVED							
TISSUE WHEREIN							
THE ADIPOSE							
DERIVED TISSUE IS							
TREATED WITH							
DNASE							
USE OF CYSTEINE	US	Unfiled					
AND CYSTEINE							
DERIVATIVES							
METHOD FOR	WO	Expired	PCT/JP2009/	10/23/2009			
WASHING CELLS			068237				
CENTRIFUGAL	EP	Abandoned		9/18/2009			
SEPARATION							
CONTAINER							
CENTRIFUGAL	US	Abandoned	13/120636	3/23/2011			
SEPARATION							
CONTAINER							
CENTRIFUGAL	WO	Expired	PCT/JP2009/	9/18/2009			
SEPARATION			066371				
CONTAINER	<u> </u>	<u> </u>					

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
USE OF ADIPOSE TISSUE CELLS FOR INITIATING THE FORMATION OF A FUNCTIONAL VASCULAR NETWORK	EP	Closed		Bac		355000	bac
USE OF CELLS DERIVED FROM ADIPOSE TISSUE FOR THE PREPARATION OF AN ANTI-TUMOR MEDICAMENT	EP	Closed					
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	AT	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	AU	Abandoned	2014323629	4/19/2016			
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	BE	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034

ACTIVE 43071750v2

PATENT REEL: 049011 FRAME: 0442

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	CA	Pending	2924883	3/18/2016			
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	СН	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	CN	Abandoned	201480063073,3	5/18/2016			
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	DE	Issued	14845486.1	4/18/2016	60 2014 011 601.9	7/5/2017	9/17/2034
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	DK	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	EP	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	ЕР	Published	17172872.8	5/24/2017			
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	ES	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	FI	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	FR	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034

ACTIVE 43071750v2

PATENT REEL: 049011 FRAME: 0444

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	GB	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	НК	Issued	17100171.2	1/6/2017	HK1226601	6/1/2018	9/17/2034
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	Œ	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	IT	Issued	14845486.1	4/18/2016	502017000110725	7/5/2017	9/17/2034
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	KR	Pending	10-2016-7008154	3/28/2016			

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	LU	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	MX	ABA Intent	MX/a/2016/ 003127	3/10/2016			
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	NL	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	NO	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	US	Published	14/917441	3/8/2016			

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	US	Expired	61/880086	9/19/2013			9/19/2014
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	US	Expired	61/977466	4/9/2014			4/9/2015
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	RU	Abandoned	2016109646	3/17/2016			
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	SE	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	WO	Expired	PCT/US2014/ 056145	9/17/2014			5/19/2016

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	ZA	Abandoned	2016/02209	4/4/2016			
REGENERATIVE CELL THERAPY FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS AND PTSD	EP	Abandoned	15747076.6	9/9/2016			
REGENERATIVE CELL THERAPY FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS AND PTSD	US	Abandoned	15/117665	8/9/2016			
ADIPOSE-DERIVED REGENERATIVE CELL THERAPY FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS	US	Expired	61/938040	2/10/2014			2/10/2015
REGENERATIVE CELL THERAPY FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS AND PTSD	WO	Expired	PCT/US2015/ 015028	2/9/2015			10/10/2016

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
ADIPOSE-DERIVED REGENERATIVE CELL THERAPY FOR POST-TRAUMATIC STRESS DISORDER	US	Expired	61/938052	2/10/2014		issueu	2/10/2015
TISSUE TRANSFER SYSTEM	US	Abandoned	14/750932	6/25/2015			
CENTRIFUGE CHAMBER	US	Abandoned	15/324596	1/6/2017			
CENTRIFUGE CHAMBER	US	Expired	62/022131	7/8/2014			7/8/2015
CENTRIFUGE CHAMBER	WO	Expired	PCT/US2015/ 039250	7/6/2015			4/4/2018
USE OF REGENERATIVE CELLS IN MITIGATING BURN PROGRESSION AND IMPROVING SKIN GRAFT INCORPORATION AND HEALING	CA.	Abandoned	2963468	3/31/2017			
USE OF REGENERATIVE CELLS IN MITIGATING BURN PROGRESSION AND IMPROVING SKIN GRAFT INCORPORATION AND HEALING	EP	Published	15847625,9	5/3/2017			

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
USE OF REGENERATIVE CELLS IN MITIGATING BURN PROGRESSION AND IMPROVING SKIN GRAFT INCORPORATION AND HEALING	US	Published	15/515870	3/30/2017		Issued	Date
USE OF REGENERATIVE CELLS IN MITIGATING BURN PROGRESSION AND IMPROVING SKIN GRAFT INCORPORATION AND HEALING	US	Expired	62/059773	10/3/2014			10/3/2015
USE OF REGENERATIVE CELLS IN MITIGATING BURN PROGRESSION AND IMPROVING SKIN GRAFT INCORPORATION AND HEALING	WO	Expired	PCT/US2015/ 053856	10/2/2015			6/3/2017
ENDOTHELIAL CELL FUNCTION	US	Unfiled					
ENDOTHELIAL CELL FUNCTION	US	Expired	62/298389	2/22/2016			2/22/2017

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
IMPROVEMENT OF ENDOTHELIAL CELL FUNCTION	US	Expired	62/463508	2/24/2017			2/24/2018
ENDOTHELIAL CELL FUNCTION	US	Expired	62/635685	2/27/2018			2/27/2019
IMPROVEMENT OF ENDOTHELIAL CELL FUNCTION	WO	Pending	PCT/US2019/ 018176	2/15/2019			10/27/2020
REGENERATIVE CELL THERAPY FOR MUSCULOSKELETAL DISORDERS	WO	Published	PCT/US2016/ 056043	10/7/2016			6/7/2019
REGENERATIVE CELL THERAPY FOR MUSCULOSKELETAL DISORDERS	EP	To be filed					
REGENERATIVE CELL THERAPY FOR MUSCULOSKELETAL DISORDERS	US	Pending	16/331427	3/7/2019			
REGENERATIVE CELLS FOR TREATING OCULAR DAMAGE	US	Expired	62/430290	12/5/2016			12/5/2017
LIPOSOMAL REGENERATIVE CELL SECRETIONS	US	Expired	62/436260	12/19/2016			12/19/2017
LIPOSOMAL REGENERATIVE CELL SECRETIONS	US	Abandoned	62/608243	12/20/2017			12/20/2018

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
CELL-LOADED	US	Abandoned	11/317422	12/22/2005		issueu	Date
PROSTHESES FOR	103	Availabiled	11/31/422	12/22/2003			
REGENERATIVE							
INTRALUMINAL							
APPLICATIONS							
METHODS OF USING	US	Issued	11/138083	5/25/2005	9597395	3/21/2017	9/4/2024
ADIPOSE TISSUE-							
DERIVED CELLS IN							
THE TREATMENT OF							
CARDIOVASCULAR							
CONDITIONS							
DEVICES AND	US	Abandoned	13/467828	5/9/2012			
METHODS FOR							
MONITORING,							
MANAGING, AND							
SERVICING							
MEDICAL DEVICES							
DEVICES AND	EP	Abandoned	5711479.5	1/12/2005			
METHODS FOR							
MONITORING,							
MANAGING, AND							
SERVICING							
MEDICAL DEVICES							
DEVICES AND	US	Abandoned	11/813579	12/13/2007			
METHODS FOR							
MONITORING,							
MANAGING, AND							
SERVICING							
MEDICAL DEVICES		<u> </u>					

Title of Invention	Country	Status	Application No.	Filing Date	Patent No.	Date Issued	Expiration Date
DEVICES AND METHODS FOR	WO	Closed	PCT/US2005/ 001267	1/12/2005			
MONITORING, MANAGING, AND							
SERVICING MEDICAL DEVICES							

TRADEMARKS

Case No.	Title	Country	Status	Application	Filing	Reg Date	Reg No.	Next
		-		No.	Date			Renewal
CYTH.031T	STEMSOURCE	US	Renewed	76/321292	10/3/2001	4/11/2006	3080039	4/11/2026
CYTH.031TD1	STEMSOURCE	US	Renewed	76/975922	10/3/2001	2/3/2004	2811603	2/3/2024
CYTH.032WAU	STEMSOURCE	AU	Renewed	1210865	11/19/2007	10/13/2008	1210865	11/19/2027
CYTH.032WCA	STEMSOURCE	CA	Registered	1136060	4/3/2002	8/28/2006	TMA671319	8/28/2021
CYTH.032WCN	STEMSOURCE	CN	Registered	6390077	11/20/2007	3/28/2010	6390077	3/27/2020
CYTH.032WEU	STEMSOURCE	EM	Renewed	2640597	4/3/2002	4/14/2004	2640597	4/3/2022
CYTH.032WKR	STEMSOURCE	KR	Renewed	45-2007- 0005218	11/20/2007	1/5/2009	45-25988	1/5/2029
CYTH.036T	CELUTION	US	Renewed	78/423221	5/21/2004	2/12/2008	3382732	2/12/2028
CYTH.036WCA	CELUTION	CA	Registered	1238400	11/19/2004	2/9/2016	TMA928520	2/9/2031
CYTH.036WEU	CELUTION	EM	Renewed	4130332	11/18/2004	11/21/2005	4130332	11/18/2024
CYTH.037WBR	CELUTION	BR	Renewed	827090188	11/22/2004	4/8/2008	827090188	4/8/2028
CYTH,037WCN	CELUTION	CN	Renewed	4375048	11/22/2004	2/7/2008	4375048	2/6/2028
CYTH.038WBR	CELUTION	BR	Renewed	827090170	11/22/2004	4/8/2008	827090170	4/8/2028
CYTH.038WCN	CELUTION	CN	Renewed	4375051	11/22/2004	2/7/2008	4375051	2/6/2028
CYTH.039WBR	CELUTION	BR	Registered	827090161	11/22/2004	6/29/2010	827090161	6/29/2020
CYTH.039WCN	CELUTION	CN	Renewed	4375050	11/22/2004	6/28/2007	4375050	6/28/2027
CYTH.040WCN	CELUTION	CN	Renewed	4375049	11/22/2004	6/21/2008	4375049	6/20/2028
CYTH.041WKR	CELUTION	KR	Renewed	45-2004- 3968	11/19/2004	6/7/2006	45-0016301	6/7/2026
CYTH.043IAU	CYTORI THERAPEUTICS	AU	Renewed	899295	12/14/2005	12/14/2005	899295	12/14/2025
CYTH.043ICN	CYTORI THERAPEUTICS	CN	Renewed	899295	12/14/2005	12/14/2005	899295	12/14/2025

100

ACTIVE 43071750v2

PATENT REEL: 049011 FRAME: 0454

Case No.	Title	Country	Status	Application No.	Filing Date	Reg Date	Reg No.	Next Renewal
CYTH.043IEM	CYTORI THERAPEUTICS	EM	Renewed	899295	12/14/2005	12/14/2005	899295	12/14/2025
CYTH.043IKR	CYTORI THERAPEUTICS	KR	Renewed	899295	12/14/2005	12/14/2005	899295	12/14/2025
CYTH.043WWO	CYTORI THERAPEUTICS	WO	Renewed	899295	12/14/2005	12/14/2005	899295	12/14/2025
CYTH.045WMX	CYTORI THERAPEUTICS	MX	Renewed	800922	8/17/2006	9/15/2006	952608	8/17/2026
CYTH.046WMX	CYTORI THERAPEUTICS	MX	Renewed	800923	8/17/2006	9/15/2006	952609	8/17/2026
CYTH.048WMX	CYTORI THERAPEUTICS	MX	Renewed	800925	8/17/2006	9/15/2006	952611	8/17/2026
CYTH.049WMX	CYTORI THERAPEUTICS	MX	Renewed	800924	8/17/2006	9/15/2006	952610	8/17/2026
CYTH.051ICN	CELASE	CN	Renewed	968466	5/28/2008	5/28/2008	968466	5/28/2028
CYTH.051IEU	CELASE	EM	Renewed	968466	5/28/2008	5/28/2008	968466	5/28/2028
CYTH.051IKR	CELASE	KR	Renewed	968466	5/28/2008	5/28/2008	968466	5/28/2028
CYTH,051T	CELASE	US	Renewed	77/343271	12/4/2007	2/17/2009	3577574	2/17/2029
CYTH.051WBR	CELASE	BR.	Registered	829752587	6/4/2008	5/21/2013	829752587	5/21/2023
CYTH.051WCA	CELASE	CA	Registered	1398731	5/30/2008	6/10/2015	TMA905824	6/10/2030
CYTH.051WWO	CELASE	WO	Renewed	968466	5/28/2008	5/28/2008	968466	5/28/2028
CYTH.056WCN	STEMSOURCE	CN	Registered	6390079	11/20/2007	3/28/2010	6390079	3/27/2020
CYTH.057WCN	STEMSOURCE	CN	Registered	6390078	11/20/2007	2/28/2010	6390078	2/27/2020
CYTH.058WCN	STEMSOURCE	CN	Registered	6390080	11/20/2007	8/21/2010	6390080	8/20/2020
CYTH.060WCN	CYTORI & Device	CN	Registered	6930844	9/1/2008	5/14/2010	6930844	5/13/2020
CYTH.060WEU	CYTORI and Design	EM	Renewed	7210041	9/3/2008	4/27/2009	7210041	9/3/2028

Case No.	Title	Country	Status	Application No.	Filing Date	Reg Date	Reg No.	Next Renewal
CYTH.061WCN	CELUTION and Design	CN	Registered	6930843	9/1/2008	2/14/2012	6930843	2/13/2022
CYTH.061WEU	CELUTION and Design	EM	Renewed	7209976	9/3/2008	5/11/2011	7209976	9/3/2028
CYTH.070T	INTRAVASE	US	Registered	77/566913	9/10/2008	12/7/2010	3886844	12/7/2020
CYTH.070WBR	INTRAVASE	BR	Registered	901496529	3/4/2009	12/4/2012	901496529	12/4/2022
CYTH.070WCA	INTRAVASE	CA	Registered	1430567	3/2/2009	2/9/2016	TMA928516	2/9/2031
CYTH.070WCN	INTRAVASE	CN	Registered	7223034	2/27/2009	11/7/2013	7223034	11/6/2023
CYTH,070WEU	INTRAVASE	EM	Renewed	8131583	3/2/2009	3/1/2010	8131583	3/2/2029
CYTH.070WKR	INTRAVASE	KR	Registered	40-2009- 9106	2/27/2009	4/30/2010	40-0821733	4/30/2020
CYTH.076WTW	CYTORI	TW	Registered	98027045	6/24/2009	6/1/2010	1412069	5/31/2020
CYTH.082ICN	CELBRUSH	CN	Registered	1040124	5/19/2010	5/19/2010	1040124	5/19/2020
CYTH.082IEU	CELBRUSH	EM	Registered	1040124	5/19/2010	5/19/2010	1040124	5/19/2020
CYTH.082IKR	CELBRUSH	KR	Registered	1040124	5/19/2010	5/19/2010	1040124	5/19/2020
CYTH.082T	CELBRUSH	US	Registered	77/886129	12/4/2009	8/31/2010	3840473	8/31/2020
CYTH.082WBR	CELBRUSH	BR	Registered	830626778	5/21/2010	8/9/2016	830626778	8/9/2026
CYTH.082WIN	CELBRUSH	IN	Registered	1969451	5/21/2010	5/21/2010	1969451	5/21/2020
CYTH.082WWO	CELBRUSH	WO	Registered	1040124	5/19/2010	5/19/2010	1040124	5/19/2020
CYTH.084WAR	CYTORI	AR	Registered	2988375	3/22/2010	2/28/2011	2425937	2/28/2021
CYTH.084WCA	CYTORI	CA	Registered	1534156	7/4/2011	1/4/2016	TMA924742	1/4/2031
CYTH.084WIN	CYTORI	IN	Registered	1937603	3/17/2010	6/25/2015	1937603	3/17/2020
CYTH.085WAU	CELUTION	AU	Registered	1603865	2/3/2014	9/3/2014	1603865	2/3/2024
CYTH.085WIN	CELUTION	IN	Registered	1937602	3/17/2010	3/6/2012	1937602	3/17/2020
CYTH.091WHK	CELUTION	HK	Registered	301699318	8/26/2010	3/8/2011	301699318	8/25/2020
CYTH.122T	HABEO	US	Allowed	87/258999	12/6/2016			
CYTH.122WEM	HABEO	EM	Registered	16662942	5/2/2017	9/1/2017	16662942	5/2/2027

Case No.	Title	Country	Status	Application No.	Filing Date	Reg Date	Reg No.	Next Renewal
CYTH.129T	CYTORI CELL THERAPY	US	Registered	87/428735	4/27/2017	6/19/2018	5495256	6/19/2028
CYTH.134T	CELUTION	US	Registered	87/164962	9/8/2016	4/18/2017	5185855	4/18/2027
CYTH,135T	CELUTION and Design	US	Registered	87/171408	9/14/2016	6/20/2017	5226684	6/20/2027
CYTH.136T	CYTORI and Design	US	Registered	87/171348	9/14/2016	1/9/2018	5372681	1/9/2028
CYTH.137T	CYTORI	US	Registered	87/165268	9/8/2016	1/23/2018	5383395	1/23/2028

ACTIVE 43071750v2

RECORDED: 04/25/2019

PATENT REEL: 049011 FRAME: 0457